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ABSTRACT    
 Sensitivity is a fundamental challenge for in vivo molecular magnetic 
resonance imaging (MRI). Here, I improve the sensitivity of metal nanoparticle 
contrast agents by strategically incorporating pure and doped metal oxides in the 
nanoparticle core, forming a soluble, monodisperse, contrast agent with 
adjustable T2 or T1 relaxivity (r2 or r1). I first developed a simplified technique to 
incorporate iron oxides in apoferritin to form “magnetoferritin” for nM-level 
detection with T2- and T2* weighting. I then explored whether the crystal could be 
chemically modified to form a particle with high r1. I first adsorbed Mn2+ ions to 
metal binding sites in the apoferritin pores. The strategic placement of metal ions 
near sites of water exchange and within the crystal oxide enhance r1, suggesting 
a mechanism for increasing relaxivity in porous nanoparticle agents. However, 
the Mn2+ addition was only possible when the particle was simultaneously filled 
with an iron oxide, resulting in a particle with a high r1 but also a high r2 and 
making them undetectable with conventional T1-weighting techniques. To solve 
this problem and decrease the particle r2 for more sensitive detection, I 
chemically doped the nanoparticles with tungsten to form a disordered W-Fe 
oxide composite in the apoferritin core. This configuration formed a particle with 
a r1 of 4,870mM-1s-1 and r2 of 9,076mM-1s-1. These relaxivities allowed the 
detection of concentrations ranging from 20nM – 400nM in vivo, both passively 
injected and targeted to the kidney glomerulus. I further developed an MRI 
acquisition technique to distinguish particles based on r2/r1, and show that three 
nanoparticles of similar size can be distinguished in vitro and in vivo with MRI. 
This work forms the basis for a new, highly flexible inorganic approach to design 
nanoparticle contrast agents for molecular MRI. 
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CHAPTER 1  
AN INTRODUCTION TO MAGNETIC NANOMATERIALS AND MRI CONTRAST 
AGENTS 
1.1 Introduction 
 Magnetic nanomaterials are useful to a wide range of potential medical 
applications, including thermal ablation, drug targeting, implantable biomaterials, 
cell tracking, and imaging contrast agent design. A detailed understanding of the 
physics of magnetism is helpful in both the creation of nanomaterials and in 
gaining an understanding of how they interact with the surroundings. Importantly, 
the understanding of material magnetism at the nanometer scale has increased 
as new materials have been developed. This increased understanding has led to 
further innovations in nanomagnetic material design and has opened the door to 
novel inter-disciplinary applications. For example, noninvasive imaging 
techniques and multimodal approaches to treatment are being advanced with an 
increased knowledge of the molecular makeup of individual patients. Concurrent 
with these rapid improvements in radiological techniques, drugs and imaging 
probes are being developed at the nanometer scale to interact with individual 
molecules in vivo with improved specificity, sensitivity, and pharmacodynamics.  
 The search for a fuller understanding of nanomagnetic materials has led 
to a bridge between very disparate academic fields. These fields ranging from 
physics, chemistry, materials science, and biology work together in 
understanding the underlying concepts of magnetic materials in the nanometer 
scale especially for the applications in medicine.  
  2 
 This thesis concentrates on the ability to tune the magnetic properties of 
materials in the nanometer scale in order to develop a rational design of 
nanoparticle contrast agents for molecular magnetic resonance imaging.  
 
1.2 The Basics of Magnetic Resonance Imaging 
 Approximately 60% of the total body weight of an adult male is water 
(Silverthorn, 2004). Magnetic Resonance Imaging (MRI) takes advantage of the 
abundance of water in the body to be able to see water content in tissues in three 
dimensions. Specifically, the hydrogen protons in water are directly imaged with 
MRI. Proton spins in a magnetic field precess at a specific frequency depending 
on the nuclei and the isotope. This frequency is known as the Larmor frequency, 
determined by the field itself, and the nuclei’s gyromagnetic ratio as follows.  
 
€ 
ω(x) = γ ⋅ B(x)         Eqn 1.  
 
 This rotational motion sets in a magnetic moment that has the tendency 
of aligning with the external magnetic field as illustrated below.   
 
Figure 1. Interaction of a proton spin with an external magnetic field (B0) creating 
a current loop around the rotating axis. Adapted from Haacke B (B. R. Haacke M, 
1999)  
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 Hydrogen protons are in constant thermal energy exchange with the 
surrounding atoms (“lattice”). When a static field is applied, the magnetic energy 
is deposited into the proton’s overall energy and the protons align with the 
magnetic field in order to reach their minimum energy state. This new equilibrium 
state is preferred every time the spin ensemble is perturbed by external RF 
energy deposited in the sample. The rate at which this state of equilibrium is 
attained is characterized by the intrinsic properties of the proton and lattice 
interactions. The magnetization growth in the longitudinal direction is constrained 
by a time constant known as T1 or “longitudinal relaxation”.  
 The interaction of the magnetization vector with its surroundings has been 
described classically with the Bloch equations. These equations are the solutions 
to the differential equation relating the time varying magnetization to the growth 
and decay in longitudinal and transverse directions, respectively.   
  
€ 
d
 
M 
dt = γ
 
M ×
 
B ext +
1
T1
M0 − Mz( ) ˆ z −
1
T2
 
M ⊥
     Eqn 2.  
    
 
 In quantum terms, a population of protons exposed to an external static 
magnetic field has spins aligned either parallel or anti-parallel to the field. These 
states are then either m = +1/2 or -1/2, being +1/2 the state of lowest energy. 
Due to conservation of energy, a single spin transition from -1/2 to +1/2 does not 
occur without a transition up in energy from the lattice (+1/2 to -1/2). The rate of 
overall energy change from +1/2 is determined using Shrödinger’s equation 
where the density of state change per unit energy is reduced as a finite state 
using a Dirac delta function. The rate of change is then identified as the spin-
relaxation decay rate.  
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€ 
d(ΔN)
dt =
(ΔN)0 −ΔN
T1         Eqn 3.
 
Where N is the initial spin state either +1/2 or -1/2. And ΔN is the spin excess of 
+1/2 over -1/2.  
 This equation is then manipulated in order to represent the magnetization 
in the z-direction and results in the following expression that matches the solution 
to the Bloch equation in the same direction where the rate of growth is 
characterized by the constant T1. 
€ 
dMz
dt =
M0 −Mz
T1         Eqn 4.
 
 Spin-spin interactions among neighboring protons are represented by the 
decay rate in the transverse plane. Given that each precessing spin gives rise to 
an individual magnetic moment, one can visualize an individual spin as a 
minuscule magnet. If multiple minuscule magnets interact with one another, their 
local magnetic fields (although very small compared to the static B0) induce loss 
of spin coherence in the transverse plane. Due to this de-phasing effect, the 
magnetization in the transverse plane decays much faster than the growth in the 
longitudinal direction. These magnetization components are also the result from 
solving the differential equation introduced above.   
 
€ 
dMx
dt =ω0My −
Mx
T2
        Eqn.5 
        
 
€ 
dMy
dt = −ω0Mx −
My
T2
        Eqn. 6  
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 There is also a contribution to the dephasing effect attributed to magnetic 
field inhomogeneities and this is described by the decay constant known as T2*.  
 Detecting the location of a specific population of spins is accomplished by 
means of their own magnetization and spatial encoding. Rotation of 
magnetization is accomplished by a “transmit coil”, a short radiofrequency 
(Karfeld, Bull, Davis, Meade, & Barron) pulse tuned to the resonance frequency 
“pushes” the magnetization vector toward a desired plane. By rotating the 
magnetization in a direction away from the equilibrium position (aligned with the 
static magnetic field) it is possible to perturb the spins and detect the changing 
flux via a secondary external coil. Much like in Faraday’s Law, a changing 
magnetic flux in a current loop induces an emf in an adjacent “receive coil”.  This 
concept is explored and used to translate changing magnetic flux of the spin-
generated magnetization into changing voltage in the receive coil.  The general 
formula that relates emf to magnetization at a specific point source is the 
following (B. R. Haacke M, 1999). 
 
  
€ 
emf = − ddt d
3r
 
M ( r ,t) ⋅  B receive ( r )
sample
∫
          Eqn 7.
 
 
 The addition of a spatially varying magnetic field confers the ability to 
spatially encode proton spins.  Once the RF pulse excites the spin ensemble, it is 
possible to encode their locations by applying a gradient as shown in the 
equation below along the x-direction. Consequently, phase is accumulated over 
time.  
 
  6 
€ 
ω(x) = γ(B0 + xGx )         Eqn 8. 
 
  As the gradient is imposed in the sample, the signal coming from the 
detection coil is stored in ‘K-space’. A typical cartesian coordinate K-space is a 
“grid” with all the signal information being stored following the following pattern.  
€ 
K = γ G(τ )dτ∫         Eqn 9. 
 Phase encoded and frequency encoded information is stored in K-space 
and translated into image space via a half-space Fourier transform.  
 Collective spins are manipulated via a pre-determined sequence of RF 
pulses and gradient sets. These pulse sequences can be tailored to highlight and 
image specific structures in the body. For example, a pulse sequence that is 
heavily weighted in T1 changes in tissue is known as T1-weighted pulse 
sequence. Similarly, sequences that are heavily weighed in T2 changes in tissue 
are known as T2-weighted pulse sequences. There are a myriad of pulse 
sequences that have been developed for various applications in the last 
decades. Acquiring the MRI signal can be done in multiple ways, most pulse 
sequences are very versatile as the acquisition and manipulation scheme have 
multiple parameters such as the echo time, repetition time, inversion time, flip 
angle etc. By carefully selecting these parameters, it is possible to weight a 
certain signal to be highly sensitive to T1, T2, diffusion coefficient, proton density 
etc.  
 Here, for simplicity, the signal equation for a spin echo pulse sequence is 
presented. 
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   Eqn 10. 
 In this equation, the signal is highly dependent on the echo times (TE), 
and repetition time (TR). The signal is weighted towards T1 tissues for a short TE 
and TR, while it is more T2 weighted when TE and TRs are long.  
 It is evident that if the intrinsic T1 and T2 could be reduced, the signal 
could be enhanced. This is the premise behind the use of exogenous contrast 
agents as they can alter the T1 and T2 of surrounding water protons and, hence, 
create local enhancement or decrease of signal. This paves the way for intensive 
research efforts towards the development of highly efficient contrast agents 
composed of magnetic materials.  
 
1.3 Magnetic Nanomaterials   
 Magnetic materials are commonly synthesized from metals, such as 
transition or rare earth metals, to form a crystal. The magnetism of a material can 
be described classically by a net magnetic moment. Single-atom, paramagnetic 
materials have localized, unpaired valence electrons that give rise to the 
magnetic moment. The magnetic moment of a paramagnet increases 
approximately linearly with the strength of an applied field. This behavior is 
described by the susceptibility, which is the slope of the magnetization vs. field 
strength. The magnetic moment of a multi-atom crystal is not necessarily related 
to the magnetic susceptibility of each single atom due to the interactions between 
the individual electronic distributions. Here, I first describe the atomic basis of 
magnetism, and then provide an overview of how magnetism is formed in multi-
atom macroscopic and nanometer-scale materials.  
€ 
S = M0(1− 2e−(TR−TE / 2)/T1 + e−TR /T1 )e−TE /T2
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 The basis of magnetism is spin, which is a fundamental property of 
matter. There are two major considerations to the interactions of electrons and 
the effect of the magnetism in solids: 1) Coulomb’s repulsion between electrons 
and attraction to protons, and 2) Pauli’s exclusion principle and the fact that 
electrons of the same spin state (up or down) cannot occupy the same orbital. 
These electromagnetic interactions result in the familiar electronic orbital around 
the atom. If the sum of these interactions results in a partially filled electronic 
shell, it creates a net magnetic moment in the atom. This is often the case for 
transition metals, leading to the complex interaction between electrons of 
neighboring atoms. The electronic distribution in transition metals can be 
complex. For example, in these metals, the 3d orbital has a localized but 
asymmetric distribution around the nucleus, while the 4s orbital has a highly 
symmetric but a broader distribution(Pepperhoff & Ancet, 2001). The collective 
interaction of electronic moments give rise to the magnetic characteristics of 
magnetic materials, usually rendering them diamagnetic, paramagnetic, 
superparamangetic, ferro/ferrimagnetic or antiferromagnetic. These 
classifications are discussed here in the context of solid nanomagnetic materials.  
 
1.3.1 Diamagnetic, Paramagnetic, Superparamagnetic and Ferromagnetic 
Nanomaterials 
 The bulk magnetic response of a material to an external field is usually 
described as its magnetic susceptibility (χ).  
M = χH        Eqn 11. 
Where M is the magnetization of the material, H is the external magnetic field, 
and χ is the magnetic susceptibility.  
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 Diamagnetic materials are often the result of no interaction between 
electronic moments because all electrons are paired. Thus, there is no residual 
spin or moment alignment with the application of an external magnetic field, and 
instead a slight repulsion. Diamagnetic materials are characterized by having a 
negative magnetic susceptibility.  
 Paramagnetic materials are defined by the nearly linear increase in 
material magnetization with an applied field, and thus by a positive magnetic 
susceptibility (χ). Typically, paramagnetism arises from atoms with magnetic 
moments that are uncoupled because the energy of interaction is much less than 
the thermal energy (kBT) of spin fluctuation. Since there is no collective 
movement of moments (long-range order), the moments act individually and 
result in relatively low overall magnetic moments.  
 
Figure 2. (Left figure) Paramagnetic magnetization as a function of applied 
magnetic field. Response is linear with no saturation magnetization visible. 
(Shaw, et al.).  (Right figure) Susceptibility (1/χ) as a function of temperature. 
Temperature axis intercepts represent the Curie transition temperature for 
ferromagnetic materials (θ>0) or the Néel transition temperature for 
antiferromagnetic materials (θ<0).  
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 There are various types of paramagnetism, Curie, Curie-Weiss, Pauli, 
and Van Vleck (McElfresh, 1994). These different types of paramagnetism are 
mainly characterized by their temperature dependence or lack there of. The 
understanding of their respective temperature response provide with unique 
insight about the electronic interactions of individual moments within the 
magnetic solids.  
 In this work, I mainly concentrate on Curie and Curie-Weiss paramagnets. 
These paramagnets have the following magnetic susceptibility: 
χ = 
€ 
C
(T −θ)         Eqn. 12
 
Where the temperature θ is non-zero for Curie-Weiss paramagnets, and zero for 
Curie paramagnets. Figure 2 illustrates how the sign of this temperature θ 
indicates the type of interaction between adjacent moments. For θ<0 the 
individual moments are known to be antiferromagnetically-coupled (Figure 2 
above). This interaction facilitates the opposite alignment between adjacent 
moments. For θ>0 the individual moments are known to be ferromagnetically-
coupled and thus adjacent moments are aligned in the same direction (Figure 2 
above).  
 Curie-Weiss paramagnets have a linear 1/χ vs. T plot (Figure 2 above). 
The temperature θ is represented in this plot as the temperature where the line 
intercepts the abscissa. For θ>0 this temperature is known as the Curie 
temperature, Tc, and therefore has a ferromagnetic transition at that temperature. 
Conversely, for θ<0 this temperature is known as the Néel temperature, TN,  
these materials possess an antiferromagnetic transition near that temperature. 
  11 
An example of Curie-Weiss paramagnets is amorphous spin-glass like materials 
in which there is some degree of long-range disorder.   
 Superparamagnetism has a stronger interaction between electronic 
moments and thus the susceptibility constant χ is much larger than 0. However, 
the response to increasing applied field yields a non-linear magnetization of the 
sample. This magnetization curve results in saturation at lower magnetic fields 
than for paramagnetic materials as seen in Figure 3. Superparamagnetism is 
strongly size-dependent as the magnetic anisotropic energy barrier is 
proportional to the product of the magnetic anisotropic constant Ku and the 
volume of the particle(Jun, Seo, & Cheon, 2008). Therefore, materials that are in 
the nanometer scale (approximately <30nm diameter) have insufficient magnetic 
energy to overcome the intrinsic thermal energy that allows for spin fluctuations. 
Thus, in the absence of a magnetic field they result in a net magnetization of zero 
and no magnetic remanence as seen in Figure 3 below.  
 
 
Figure 3. Magnetization as a function of external applied magnetic field. 
Superparamagnetic materials possess full reversibility and saturation 
magnetization, Ms, as an intrinsic property of the materials.  
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 The surface of nanomagnetic materials have more spin-glass like 
characteristics, where the individual spins lack coupling with one another due to 
surface defects and mainly due to structural disorder. As the size of the 
nanoparticle shrinks, then the volume ratio between the surface-disordered spins 
and the overall particle volume increases resulting in a reduced saturation 
magnetization and tipping the susceptibility closer to the paramagnetic regime as 
shown previously in ultra small nanoparticles (B. H. Kim, et al., 2011). 
  When atoms are coupled through shared electrons, such as in a crystal 
oxide, the magnetization also increases with the applied field. In certain 
nanoparticles, when the external magnetic field is removed, the magnetization 
remains fixed with finite remanence and coercivity (Mr and Hc). These materials 
are known as “ferromagnetic.”  The magnetization remains fixed in orientation in 
these materials because the thermal energy is not sufficient to overcome the 
coupling between spins in the material through the anisotropy energy.  
 Most nanoparticles are ferromagnetic due to the formation of magnetic 
domains within the crystals. But in some cases single-domain nanoparticles are 
still ferromagnetic because they possess an unusual magnetic anisotropic energy 
that result in a finite coercivity that is characterized by the following relationship 
(Jun, et al., 2008).  
 
€ 
Hc =
2ku
Ms
1− 5(kBTkuV
)
1
2
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Where Ms is the saturation magnetization of the sample, ku is the magnetic 
anisotropic constant, kb is the Boltzmann constant, T is the temperature, and V is 
the particle volume.  
 Conceptually, domains represent a volume of homogeneous 
magnetization inside the crystal, although the domain can be dynamic and 
variable in size.  
 
 
Figure 4. Schematic showing magnetic domains in a nanoparticle and their 
movement along their easy-axes in order to align with the external magnetic field. 
Adapted from (McElfresh, 1994).  
 
 The above figure illustrates the formation of magnetic domains, not to be 
confused with crystallographic domains, and their movement in order to have all 
moments align with the applied external magnetic field. Coercivity mainly results 
in the inability for these domains to return to their original states unless an 
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additional reversal field is applied. When the field strength is reversed from 
magnetic saturation, domains return to their preferred crystallographic positions. 
Upon further field reversal, domain walls start to move towards their original 
states. However, due to the presence of grain boundaries, defects, and 
inclusions within the crystal, this movement is sometimes impeded. Thus, full 
return to the initial magnetic domain position is not accomplished resulting in 
residual magnetization (magnetic remanence Mr) as illustrated in Figure 5.  
 
Figure 5. Magnetization reversal experiment on a ferromagnetic material. 
Magnetization curve shows the virgin curve initially formed when the material is 
first magnetized. Upon reversal from saturation, Ms, the sample shows 
irreversibility and displays a remanent magnetization, Mr, when the applied field 
is absent (H=0). A negative field is needed to return the magnetization to zero 
(Hc). Adapted from (McElfresh, 1994) 
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 These principles and magnetism mechanisms of nanomagnetic materials 
are the basis for nanoparticle-based contrast agents. Although magnetic 
materials are widely understood and explained in a phenomenological manner it 
is crucial to obtain full understanding of the underlying spin mechanisms. 
Understanding the magnetization process at the level of individual and collective 
spins is of uttermost importance when designing magnetic materials in the 
nanometer scale as contrast agents for MRI.  
 
1.4 Contrast Agent Relaxivity  
 Recent advances in targeted molecular imaging have made it possible to 
image molecular events in vivo with MRI. Many of the probes used for molecular 
imaging involve the use of synthetic iron oxide nanoparticles for T2 and T2* -
imaging, and chelates of paramagnetic ions for T1-weighted imaging. Due to the 
inherent insensitivity of MRI to detect molecular probes, there is a need to 
develop techniques to synthesize higher relaxivity agents in order to use them as 
molecular probes for in vivo MRI. This sensitivity can be quantified by the agent’s 
relaxivity (Querol & Bogdanov, 2006). Relaxivity is defined as the rate of 
relaxation of water protons in 1mmol/L solution of agent.  
   
€ 
1
Tx
=
1
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+ rx ⋅C     x = 1, 2                            Eqn. 14 
 
Per Equation 14, the term rx determines the concentration that can be detected 
(Aime, Castelli, Crich, Gianolio, & Terreno, 2009; B. R. Haacke M, Thompson M, 
Venkatesan R, 1999b; Querol & Bogdanov, 2006) over background.  
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Figure 6. Intrinsic T2 and T1 relaxation times of different tissues in vivo at 3T and 
1.5T. Reprinted with permission from (Stanisz, et al., 2005). Copyright John 
Wiley and Sons, 2005. 
 
 Intrinsic tissue background is an important parameter to consider when 
designing ultra-sensitive nanoparticle contrast agents for molecular MRI. Stanisz 
et al. introduced a comprehensive list of relaxation times for different tissues 
based on literature and experimental results (Figure 6). It is evident that for most 
tissues their intrinsic longitudinal relaxation rate is much longer than the 
transverse relaxation rate in vivo and at different field strengths. This offers an 
advantage for T1-weigthed over T2 - weighted imaging to detect lower 
concentrations in vivo.  As shown in figure 7 below, it is clear that T1-shortening 
contrast agents do not require as high of a relaxivity in order to attain lower 
concentrations in vivo.  
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Figure 7. (Top plot) Simulated minimum concentrations that can be detected 
assuming an arbitrary minimum 10% change from signal to background for T1-
shortening agents and 20% change for T2-shortening agents. (Bottom plot) 
Simulated detection window based on agents with increasing r2/r1.  
 
 Though an agent can have a high T1 relaxivity (r1) its corresponding r2 is 
important in order to assess its ability to be detected. As the r2/r1 increases for 
any specific agent, the detection window narrows as the agent starts becoming 
more of a T2- shortening agent than a T1-shorteing agent. This is illustrated in 
Figure 7 bottom panel, where it is evident that the concentration range at which 
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the agent can still be considered a T1-shortening contrast agent decreases as its 
r2 effect increases and overrules the r1 effects in surrounding water. Therefore, 
for a wider concentration range of detection, T1-shortening contrast agents are 
most desirable when its r2/r1 is as low as possible. The ability to tune the r2/r1 of a 
specific particle could provide with a pathway for more sensitive detection of 
molecular events in vivo. In order to tune each relaxivity individually, it is 
important to understand the interactions between the different magnetic materials 
and the surrounding water and their effects on the overall MRI signal. In order to 
attain this understanding, I discuss two well-known models for longitudinal and 
transverse relaxation effects on the water protons.  
  
1.4.1 Solomon Bloembergen Model of Dipolar Longitudinal Relaxation and 
 Coordination Spheres  
 
 The Solomon-Bloembergen-Morgan (SBM) equations model the dipolar 
relaxation rate of water protons due to the effect that a paramagnetic moment 
has on the bulk water T1 relaxation. This model also describes the overall 
longitudinal relaxation rate to be the product of multiple contributions. These 
contributions are determined by the theory of coordination spheres (Caravan, 
Farrar, Frullano, & Uppal, 2009). More specifically, the observed relaxation rate 
(r1obs) is the sum of the relaxation rates of water located within each of the 
coordination spheres. 
This is: 
r1obs = r1IS + r1SS + r1OS        Eqn.15 
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Where, r1IS is the inner sphere relaxivity, r1SS is the second sphere relaxivity, and 
r1OS is the outer sphere relaxivity. The inner sphere (IS) is defined as water that is 
directly bound to the paramagnetic ion. The second sphere (SS) is defined as 
water that is bound weakly to ligands that are farther away from the 
paramagnetic ion, and therefore it is mostly a chemical exchange mechanism. 
And finally, the outer sphere (OS) is mostly the contribution from bulk water 
diffusion surrounding the agent at longer distances from the paramagnetic ion. 
For the purposes of this model its contribution is assumed to be constant (2mM-
1s-1)(Caravan, et al., 2009). 
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Where, q is the hydration number, τM is the water residence time, T1 is the dipolar 
longitudinal relaxation rate, [H2O] is the bulk water concentration, µ0 is the 
permittivity of vacuum, µB is the Bohr magneton,  γH is the gyromagnetic ratio, rMH 
is distance between the electron spin of the paramagnetic metal and the proton 
spin of the water molecule in the corresponding coordination sphere, ωH is the 
larmor frequency at 1.5T, τc is the overall correlation time and τR is the rotation 
correlation time, which can be calculated using Stoke’s equation.  Based on 
equation xx the dipolar relaxation rate is easily modulated by the distance 
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between the electronic moment of the paramagnetic atom and the water proton 
moment.  
 All these equations have been used to predict the longitudinal relaxation 
that a single paramagnetic nucleus (Gd3+ or Mn2+ macrocyclics and chelates) 
imposes on the surrounding water. Therefore, for nanoparticle based 
paramagnetic contrast agents the only moments contributing to an overall water 
longitudinal relaxation are those of the surface and in close contact with water 
protons.  
 
1.4.2 Chemical Exchange Model and Static Dephasing Regime for Transverse 
Relaxation  
 Similar to the longitudinal relaxation model that, relies on the dipolar 
interaction between the unpaired electron magnetic moment and the proton 
moment. The transverse relaxation model relies on the interaction of the 
magnetic moment and the dephasing of the surrounding water protons in the 
transverse plane.  
 In a medium with magnetized particles, as the particles become partially 
aligned with the external magnetic field, their induced magnetization creates a 
field gradient around the particle since the magnetic susceptibility constant is 
much greater than that of paramagnetic particles or atoms.  Thus, there is a 
difference in local frequencies that water protons experience as they diffuse in 
and out of the local gradient field or bind and unbind to the particle surface that 
lead to an accumulation of different spin phases through the sample prior and 
during data acquisition (Yablonskiy & Haacke, 1994).  
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 Transverse relaxation shortening due to magnetized particles is 
modulated mainly by the following parameters: 1) the particle size, 2) the 
measurement half echo time (τcp) and 3) the diffusion time (τD). As the size of the 
particle is not large enough to create large surrounding magnetic 
inhomogeneities, the chemical exchange model is an appropriate model for the 
transverse relaxation of the medium. Thus, a model for weakly magnetized 
particles where the maximum dephasing during an echo interval is less than one 
radian is considered. This is τCP < 1/Δω.  
Therefore, according to the chemical exchange model introduced by Gillis and 
coworkers and assuming a long echo limit, the transverse relaxation is described 
as the following (Brooks, Moiny, & Gillis, 2001). 
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Eqn.19 
In the static dephasing regime, where particles are strongly magnetized, the 
mechanism for transverse relaxation is modulated mostly by the diffusion of the 
water molecules through the magnetic field created by the magnetized 
nanoparticle. Thus τD is on the order of the time that it takes for a water molecule 
to diffuse a distance comparable with the field-creating object (Yablonskiy & 
Haacke, 1994). Since τD increases proportionally with the size of the particle, the 
motional averaging effect is diminished setting a maximum for r2 for any material.  
Then R2 is described as follows. 
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 As outlined in Weissleder et al, the relaxivities can be modeled using 
these equations taking into account the particle size, magnetization and particle 
lattice parameters (Yoon, Lee, Shao, Hilderbrand, & Weissleder, 2011). 
 
1.5 Engineering High Relaxivity Nanoparticle Contrast Agents 
 Since the efficiency of the agent can be quantified by its T1 relaxivity (r1) 
and T2 relaxivity (r2), I investigate the mechanisms to increase these relaxivities 
to be able to attain detection of agent at relevant biological concentrations. 
Current techniques to increase r1 in nanoparticles usually involve increasing the 
paramagnetic metal payload per nanoparticle. However, the sensitivity for 
detection with these methods is still in the nanomolar to micromolar range. 
Therefore, there is an increasing need to design nanoparticle based contrast 
agents of high efficiency such that they can be detected at concentrations that 
are relevant for molecular imaging.  
 
1.5.1 Chemical Doping   
 The ability to tune the magnetization of crystals by altering their 
composition has helped in the design of magnetic materials. Here, I concentrate 
mainly in oxide-based crystal structure manipulation.  
 The manipulation of oxides relies mostly on the concept of 
superexchange. In ionic solids superexchange operates by coupling localized 3d 
electron moments from transition metal cations. In an antiferromagnetic 
crystalline structure such as that of MnO for example, the transition metal 
magnetic moments align antiferromagnetically with respect to each other. This is, 
the spins in the transition metal cation located in the same (111) plane are 
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aligned parallel. But the nearest cation plane spins are aligned in the other 
direction. Regular Heisenberg exchange interaction must occur in an indirect 
manner since the cations are located too far apart to have wavefunction overlap. 
This exchange coupling is accomplished only via a mediator. In the case of the 
MnO lattice, the mediator is the Oxygen anion located in between planes. The 
oxygen anion p orbital exchanges an electron with the 3d orbitals from the 
transition metal cation.  The symmetry and the spin orientation (up or down) 
localization in the p anion versus the d cation allows for electron spin orientation 
conservation and thus for antiferromagnetic coupling of transition metal cation 
neighbors (O'Handley, 2000).  
 Since both cations possess the same 3d electronic configuration the 
magnetic moments for each cation is the same and thus “cancel each other out”. 
Contributing with no net magnetization. Naturally, one could assume that if the 
electronic configuration of one of the 3d cations were to be different, the 
magnetic moments would not “cancel out” and thus, result in an observed net 
magnetization in the crystal. This is where “doping” of crystals helps in increasing 
the net magnetization. One example of doping is the use of a mixed valence 
cation electron crystal such as magnetite. The formation of a lattice that is 
comprised of Fe3+ and Fe2+, with 3d5 and 3d6 electronic configurations, 
respectively, leads to an un-even antiferromagnetic coupling. Although the lattice 
structure in iron oxides are much more complicated than the previous rock salt 
example, the superexchange phenomenon still holds.   
 Iron oxide crystal structures that possess a net magnetization are usually 
arranged in a spinel structure. This atomic configuration is very complex and the 
bonding is no longer linear (i.e. Transition metal-Oxygen-Transition metal).   
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Spinel structures have two preferential sites for cation dopant localization. These 
sites are known as tetrahedral (Silverthorn) and octahedral (Oh) sites. In this 
structure these sites are antiferromagnetically coupled and experience 
superexchange facilitated by the oxygen anions in the lattice. Figure 8a shows 
the sublattice organization for a spinel lattice structure. Either one of the sites can 
be substituted with transition metal cations that can allow d-p orbital overlap. In 
Lee and coworkers, for instance, examples of ferrite doping included the 
substitution of Fe2+ or Fe3+ with Ni2+, Mn2+, Co2+ and Fe2+in either Oh or Th(Lee, et 
al., 2007). The change in oriented magnetic moments in the crystal by doping led 
to a net magnetization that was largest for Mn2+ doped and lowest in Ni2+ doped 
ferrites (Figure 8b). This effect corresponded to the maximum saturation 
magnetization and relaxivity coefficient for Mn2+ doped ferrites and the minimum 
for Ni2+ doped ferrites (Figure 8b and c).  
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Figure 8. Ferrite spinel crystal structure illustrating possible octahedral (Oh) and 
tetrahedral (Silverthorn) dopant occupancy sites (a). Unit cell spin moments for 
magnetically engineered ferrites with Mn2+, Fe2+/3+, Co2+, and Ni2+ doping (b) 
Respective mass magnetization values for Mn, Fe, Co, and Ni doped ferrites and 
their relaxivity coefficients (c). (b-c) Adapted and reprinted with permission from 
(Lee, et al., 2007) Copyright 2007 Nature Publishing Group.   
 
1.6 Ligand and Crystal Field Manipulation of Spin State 
 Most inorganic nanoparticle based contrast agents are synthesized using 
3d transition metal atoms either in the form of an oxide or an alloy. Coulomb 
interactions between the ligand and the metal atom electrons give rise to the 
crystal field configuration. The most common configuration is octahedral where 6 
ligands come together and coordinate the metal atom, however, tetrahedral, 
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square planar, square pyramidal and other arrangements are also possible. The 
crystal field splitting arises from the arrangement and the location of the ligand 
bonding electrons with respect to the metal d-orbitals. Orbitals that are closer to 
the ligand will have a higher energy than orbitals farther away from the ligands.  
 Bonding between atoms in an oxide is facilitated by d-orbital overlap with 
surrounding atom orbitals of lower energy and appropriate symmetry, most of the 
cases p-orbitals. This bonding gives rise to the delocalization of electrons moving 
from the ligand to the coordinated metal. The classification of the ligand is 
determinant of the metal atom orbital energy splitting. The following is a list of 
common ligands and their classification based on their ligand field.  
 
 A strong field ligand coordinated to a 3d transition metal atom will split the 
degenerate state into t2g and eg states, where the pairing energy is lower than the 
electron orbital transition energy. For example, Fe2+ is a 3d6 system with 6 
electrons ready to occupy the 5 d-orbitals. When bound by a strong field ligand 
the energy splitting among the orbitals is increased making the electrons 
energetically more likely to pair first than to move toward higher energy orbitals. 
This changes de degenerate state to a low-spin configuration as illustrated in the 
figure below. Adopting a low spin configuration could then lead to a change in 
overall magnetic moment per atom. In this example, the coordination to a strong 
field ligand resulted in a change in the atom’s magnetic properties. Mainly, a 
change from being paramagnetic to diamagnetic.  
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Figure 9. Spin configuration for Fe2+. Left system shows the degenerate state for 
the 3d6 system. Once coordinated to a strong field ligand, the spin configuration 
is that of a low spin system resulting in diamagnetism due to lack of unpaired 
electrons.  
 The rational selection of a ligand in the synthesis of a metal based 
magnetic material can provide the ability to induce a low spin or high spin 
configuration, which then can be used to manipulate the coupling and 
delocalization of magnetic moments within a crystal lattice and consequently the 
overall material magnetic properties.  
 
1.7 Current Efforts on the Increase of Nanoparticle Based Contrast Agent 
Relaxivity 
 Macromolecules containing multiple paramagnetic ions are used to 
change the longitudinal relaxation rate, R1 (Accardo, et al., 2007), which typically 
brightens the MR image. Some common structures are liposomes, micelles, 
dendrimers, and peptides. The purpose of these structures is to increase the 
contrast agent metal payload in order to increase relaxivity. Paramagnetic 
macromolecular structures can be either biological or synthetic molecules.  One 
example is the molecule developed by Karfeld et al (Karfeld, et al., 2007), with an 
engineered protein providing the backbone and repeating free lysines conjugated 
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to gadolinium chelates, achieving a per-agent r1 of 62.6 mM-1 s-1. Song et al. 
used small, synthetic, biocompatible molecules to increase the r1 of individual 
Gd(III) complexes by hindering the local rotation of the Gd(III) complex (Song, 
Kohlmeir, & Meade, 2008). Synthetic and biological molecules that include 
multiple gadolinium chelates are similar to nanoparticles in relaxivity, but have 
the advantage of structural flexibility; their backbone can be specifically designed 
for target delivery and membrane permeability, to carry other small molecules, or 
to bind to target tissue.  
 Recently, several porous nanostructures have been reported to greatly 
enhance paramagnetic relaxivity at clinical field strengths (~1.5T); their 
mechanisms are both intriguing and poorly understood.  For instance, 
Sitharaman et al. developed “gadonanotubes” where Gd3+ ions were loaded onto 
the side-wall defects of single-walled carbon nanotubes (Sitharaman, et al., 
2005). The reported per Gd3+ relaxivity was 173 mM-1s-1. Metal-doped carbon 
nanostructures are now being developed as a platform for increasing MRI 
relaxation (Choi, et al., 2007; Faraj, et al., 2009; Miyawaki, et al., 2006; 
Sitharaman & Wilson, 2006). Allen et al. bound Gd3+ to metal binding sites on the 
cowpea chlorotic mottle virus protein coat to obtain a per-ion r1 of 202 mM-1s-1 
(Allen, et al., 2005).  A better understanding of the mechanisms of these types of 
agents may lead to new routes to develop high relaxivity T1 (1/R1) agents. Others 
have investigated how altering the metal content of a superparamagnetic 
nanoparticle can improve per-particle relaxivity; for example, Seo et al reported 
an iron-cobalt alloy crystal inside a graphite shell with a per-particle r1 of 1.57x106 
mM-1s-1 and a r2 of 6.47x106 mM-1s-1 (W. Seo, et al., 2006).    
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1.8 Biological considerations for the Design of Nanoparticle Based Contrast 
Agents 
 The main biological considerations for nanoparticle based contrast agents 
are delivery, conjugation/functionalization, and toxicity and clearance after 
contrast agent administration.  
 The most important requirement is that the nanoparticles reach the 
intended target following systemic administration. Due to the active biochemical 
response of the host organism to the “foreign body” upon introduction, surface 
modifications are needed to the nanoparticles so as to prevent or reduce the 
“detection” and “elimination” by the body’s natural response system before the 
destination is reached.  Surfactants and surface ligands used in the synthesis 
procedures not only control the growth of particles during synthesis but also act 
as a coating that can ensure stable dispersion of particles in solution and prevent 
aggregation. These coatings may also provide stealth properties to the particles 
and enable avoidance of body’s clearance mechanisms (Harris & Chess, 2003). 
However for in vivo use of these particles, further modifications of the surface 
coating may be necessary. The clearance route or accumulation of the particles 
in various organs depends on many factors such as size, shape and charge (M. 
Longmire, P. L. Choyke, & H. Kobayashi, 2008).  Due to the leakiness of tumor 
vasculature and poor lymphatic clearance, “preferential” delivery and 
accumulation of nanoparticles as well as most small molecules is often observed 
in tumors through the enhanced permeability and retention effect (Maeda, Wu, 
Sawa, Matsumura, & Hori, 2000). Apart from such passive targeting, the targeted 
delivery and retention of nanoparticles into specific tissue of interest is of great 
interest for researchers developing diagnostic, theranostic, or therapeutic nano-
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probes.  Much research has focused on designing probes that “recognize” the 
vasculature or extravascular microenvironment of diseased tissue and display 
increased retention in such tissue over time while being cleared out of the normal 
tissue. Many biomolecules, such as small molecules, peptides, proteins, 
aptamers and antibodies have been identified that display specific affinities to the 
tissue microenvironment mediated by interactions with receptors on vascular 
endothelium or tissue cell surface. Following binding at the cell surface the 
particles can then be internalized and retained within the cells for a longer period. 
Such biomolecules have also been exploited for targeted delivery by attaching 
them to nanoparticles(Brannon-Peppas & Blanchette, 2004).  
 Conjugation of biomolecules to magnetic nanoparticles is a complicated 
multi-step process and has been reviewed recently (Sperling & Parak, 2010; 
Veiseh, Gunn, & Zhang, 2010). The choice of the core nanoparticle, ligand 
molecules that form the shell coating and targeting biomolecule are all critically 
dependent on the application. Typically conjugation techniques involve chemical 
or physical binding of the targeting moiety to the surface coating polymer. 
Chemical strategies involve covalent linkage strategies such as direct 
conjugation using the recently developed click chemistry approaches or use of 
linkers, while physical binding is based on electrostatic (E. Schellenberger, et al., 
2008; Yiu, McBain, Lethbridge, Lees, & Dobson, 2010), hydrophilic/hydrophobic 
(Dilnawaz, Singh, Mohanty, & Sahoo, 2010; Jain, et al., 2008; Yu, et al., 2008) or 
affinity-based interactions (Artemov, Mori, Okollie, & Bhujwalla, 2003; Gunn, et 
al., 2008). The specific conjugation strategy depends on the physicochemical 
properties the coating polymer and ligand to be linked and functional groups 
found on these. Detailed conjugation strategies are outlined in the literature 
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(Hermanson, 2008; Jolck, Feldborg, Andersen, Moghimi, & Andresen, 2011; 
Moghimi, Hunter, & Murray, 2001; Sperling & Parak, 2010; Veiseh, et al., 2010). 
The most important consideration is the continued ability to target the receptor 
despite chemical modifications. This necessitates binding of the ligand to the 
nanoparticle at a location away from the receptor recognition site. Direct covalent 
bonds can be formed between functional groups found on the nanoparticle shell 
and ligands to be conjugated. The choice of the polymer for the nanoparticle 
shell determines the type, number and location of these functional groups, which 
often also play a role in binding to the nanoparticle surface as well. Hence, 
polymers such as dextran, chitosan, or poly(ethyleneimine), bearing functional 
groups on the body, coat the nanoparticle with the backbone parallel to the 
surface, while polymers like poly(ethylene glycol) or phospholipids, with active 
groups at terminal ends, coat the nanoparticle with backbone parallel to the 
radius and form radial extensions similar to micelles or liposomes. Radial 
coatings can provide better steric access to the ligand for binding but the 
coupling to the nanoparticle may be less stable. Co-polymers (e.g. poly (acrylic 
acid)- poly(ethylene oxide)) can achieve both of the above effects; they can coat 
the nanoparticle surface uniformly and also provide  binding sites for the ligand 
with less steric hindrance.  
 In direct reactions, functional groups such as amines, sulfhydryls, 
aldehydes, and thiols are directly bonded to reactive ligands, in some cases with 
the help of catalysts (Weissleder, Kelly, Sun, Shtatland, & Josephson, 2005). 
These strategies are particularly suitable for small molecule conjugation. 
Biomolecules may require modification prior to conjugation, thus increasing the 
likelihood of losing targeting ability unless modifications are minimal (E. A. 
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Schellenberger, Weissleder, & Josephson, 2004). Recently, a series of Cu-
catalyzed azide–alkyne chemical reactions that are orthogonal to those of 
functional groups present within biological systems have enabled the selective 
tagging of biomolecules (Best, 2009; Hein, Liu, & Wang, 2008; Kolb, Finn, & 
Sharpless, 2001; Lutz & Zarafshani, 2008). These so called “click” reactions are 
highly specific, fast, efficient and require a relatively neutral pH aqueous 
environment (Best, 2009). A disadvantage is that these reactions require Cu as a 
catalyst and hence require its complete removal for in vivo use. Click chemistry 
has been used to attach cyclic LyP-1 targeting peptides to superparamagnetic 
iron oxide nanoparticles and used to target p32-expressing MDA-MB-435 cells in 
vitro and in vivo (von Maltzahn, et al., 2008). An alternate approach to covalent 
binding of ligands to magnetic nanoparticles involves the use of intermediate 
heterobifunctional linker molecules, which allows control over the orientation of 
bound ligands, thus potentially protecting targeting ligand functionality. Using the 
linker approach, magnetic nanoparticles have been conjugated to transferrin 
(Hogemann, Josephson, Weissleder, & Basilion, 2000), annexin V (E. A. 
Schellenberger, Sosnovik, Weissleder, & Josephson, 2004), folic acid(Kohler, 
Fryxell, & Zhang, 2004), chlorotoxin(Sun, et al., 2008; Veiseh, et al., 2005) 
siRNA(Medarova, Pham, Farrar, Petkova, & Moore, 2007), aptamers (Wang, et 
al., 2008) and HER2 antibody(Dilnawaz, et al., 2010).  
 The toxicity of a magnetic material depends on the material 
concentration, the organ or cell to which it is targeted, and the material chemical 
composition. Macromolecules such as dendrimer agents with conjugated 
paramagnetic ions are being developed with a wide range of specificity, 
biodistribution and enhanced magnetic properties(Bumb, Brechbiel, & Choyke; 
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Wiener, et al., 1994). Nanoparticle toxicity and clearance are active areas of 
investigation (M. Longmire, P.L. Choyke, & H. Kobayashi, 2008). The size and 
surface chemistry of a particle often determines whether the particle will reach 
and bind to a molecular target. In some instances, natural nanoparticles are 
desirable for both delivery and biocompatibility (Cormode, Jarzyna, Mulder, & 
Fayad, 2009). For example, cationized ferritin, a 13 nm protein-based iron oxide 
nanoparticle, is small enough to pass through the endothelial fenestrations on the 
kidney glomerular capillary wall (Bennett, Zhou, et al., 2008) and is able to bind 
to the anionic proteoglycans of the glomerular basement membrane(Beeman, 
Zhang, et al.). Furthermore, there are a number of particles designed to target 
over-expressed ligands in cancer cells as well as particles targeted to 
atherosclerotic plaques(Frias, Williams, Fisher, & Fayad, 2004; Nasongkla, et al., 
2006). Some challenges to delivery in solid tumors include the increase in 
parenchymal pressure due to poor lymphatic drainage and increased 
extracellular matrix density. To overcome nonspecific retention, molecules have 
been developed with high target specificity, so that they are detected after low-
dose intravenous injection. For example, Handl et al. and others have created 
multivalent peptides that bound with higher specificity to its ligand than the 
monovalent counterpart (Handl, et al., 2007; Li, Martin, & Gillies, 2007; Xu, et al., 
2010; Xu, et al., 2009). Substantial physical barriers also prevent intravenously 
injected nanomaterials from reaching the target, and researchers have 
developed several emerging techniques that temporarily pass agents through 
these barriers using ultrasound, osmolar agents, or antibodies (Hynynen, 2008; 
Johansson, 1992; Kinoshita, 2006; C. H. Liu, D'arceuil, & De Crespigny, 2004; H. 
L. Liu, et al., 2010; Madsen & Hirschberg, 2010), or through intrathecal injection 
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(C. H. Liu, et al., 2004) or convection enhanced delivery (Bobo, et al., 1994; 
Lonser RR, 2002).   
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CHAPTER 2  
FERRITIN AS A NATURAL CONTRAST AGENT  
 
2.1 Introduction  
 There are several commercially available and synthesizable nanoparticle 
contrast agents. Most of them are about 50 nm in size or larger, though some 
have recently been created in the 10 nm range (Ocean Nanotech, Springdale 
AR). Natural nanoparticles, such as ferritin, may have some advantages over 
synthetic nanoparticles for in vivo use as discussed in previous articles(Cormode, 
et al., 2009). Ferritin is a 13 nm protein nanoparticle with an iron oxide core. 
Ferritin has been used as a targeted contrast agent, and is small enough to be 
delivered through fenestrated endothelia (Bennett, Zhou, et al., 2008). Because 
native ferritin is only partially filled with a weakly superparamagnetic iron core, it 
has been reconstituted to fully fill the protein core with highly magnetic iron oxide 
cores to increase its MRI transverse relaxivity (Bulte, Douglas, Mann, Frankel, 
Moskowitz, Brooks, Baumgarner, Vymazal, Strub, et al., 1994). The efficacy and 
kinetics of ferritin as an in vivo agent were first reported to provide negative 
contrast to the liver, spleen and limph nodes when injected systemically (Bulte, et 
al., 1995). 
The T2 relaxivity of native ferritin is 1-10mM-1s-1 (Bennett, Shapiro, Sotak, 
& Koretsky, 2008). About tens of µM of native ferritin would be required to detect 
a 20% difference in shortened signal in grey matter tissue (assuming an intrinsic 
T2 of 100ms (B. R. Haacke M, Thompson M, Venkatesan R, 1999a)). 
Reconstituted "magnetoferritin" has been reported using chemically (Meldrum, 
Heywood, & Mann, 1992) or genetically modified ferritin (Uchida, et al., 2008). 
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Previous preparations of magnetoferritin have yielded a moderate r2/r1 ratio, and 
required relatively complicated synthesis techniques. In this chapter, I present a 
simple chemical procedure to create a superparamagnetic magnetoferritin using 
commercially available apoferritin, with about a 25-fold increase in per iron 
relaxivity over native ferritin and an r2/r1 of 1114. The magnetoferritin particles 
consistently stuck in a magnetic column, allowing them to be easily isolated and 
filtered. The resulting nanoparticles were made monodisperse and readily 
transferred between buffers to be functionalized.  This work should make it 
possible to quickly and simply create uniform, functional nanoparticles for 
molecular MRI inside an endogenous protein.  
 
2.2 Materials and Methods 
2.2.1 Materials  
 Apoferritin from horse spleen (Sigma Aldrich), Iron (II) Chloride (Sigma 
Aldrich, 98%), 2 - N - Morpholino Ethane Sulfonic Acid (Alfa Aesar, 98%), and 
Bovine Serum Albumin (Pierce Biotechnology) were used as received. Anti-horse 
spleen ferritin antibody (Sigma Aldrich) was diluted 100 times prior use for 
immunoprecipitation experiments.  
 
2.2.2 Simplified Synthesis of Magnetoferritin 
 The technique presented here is derived from various synthesis schemes 
(Kasyutich O, 2008; Meldrum, et al., 1992; Webb, Frame, Zhao, Lee, & Watt, 
1994; Wong K.K.W, 1998) but uses horse spleen apoferritin and magnetic 
filtration to make monodisperse magnetoferritin. I suspended 2µM apoferritin 
(Sigma Aldrich, St Louis) or bovine serum albumin (BSA) (Pierce Biotechnology, 
  37 
Rockford) in 0.05M MES buffer, pH 8.5. I prepared 48mM Fe (II) Chloride (Sigma 
Aldrich, St. Louis) in a separate flask. Both solutions were de-gassed with N2 gas 
(50psi). The apoferritin or BSA solution were kept in a water bath at a constant 
temperature of 55-60°C, the pressure of the N2 gas was reduced until no bubbles 
were formed. Every ten minutes, I then added 125µl of Fe(Miyawaki, et 
al.)Chloride to the de-gassing apoferritin or BSA solution and mixed with a 
pipette. The solution was covered with a rubber bung and sealed with paraffin 
film. This procedure was repeated a total of 20 times until the solution turned a 
slightly gray-turquoise color. The sample was removed and dialyzed overnight 
against 0.15M NaCl using a 10,000 MW cut off Dialysis Cassette (Pierce 
Biotechnology. Rockford, IL) and filtered magnetically with a micro magnetic 
column (Miltenyi Biotec. Gladbach, Germany), into 150 mM NaCl buffer (pH=7.4).  
 
2.2.3 Protein and Metal Concentration Assays 
 The resulting protein concentration was obtained using the Better 
Bradford Assay (Thermo Scientific, Rockford). Briefly, known serial dilutions of 
Bovine Serum Albumin (BSA) were stained with Coomassie Plus Reagent. The 
reagent binds with certain aminoacids, which in turn result in a spectral shift 
(from brown to blue). This shift can be measured using a spectrophotometer or a 
plate reader measuring absorbance at around 595nm. For the experiments 
presented in this work, a wavelength of 570nm was used. The Bovine Serum 
Albumin concentrations and absorbances are used as a standard curve and the 
unknown sample concentrations are obtained interpolating their absorbance to 
those of the BSA standard curve.  
  38 
 Metal concentrations were obtained by means of Inductively Coupled 
Plasma-Optical Emission Spectroscopy. Briefly, the unknown samples were 
suspended in a solution containing 2% Nitric Acid. The acidic sample solution 
was then sprayed into the plasma flame from the ICP-OES where the molecules 
of interest collide with the electrons from the plasma flame and produce radiation 
at specific wavelengths. This radiation is categorized by wavelength and intensity 
to determine the concentration of each element of interest. Similarly to the 
protein colorimetric assay, a standard curve is used as a reference to determine 
the overall sample metal concentrations.  
 
2.2.4 Electron Microscopy 
Samples were adsorbed on 400 mesh formvar coated carbon-copper 
grids (Pacific GridTech, San Francisco, CA). 50µl of magnetically filtered 
particles were placed on paraffin film and a grid was placed on top of the drop 
(formvar film side on sample). The sample was adsorbed for 5 minutes and 
excess water and sample were removed by slightly touching the edge of the grid 
with filter paper. Transmission electron microscopy (Artemov, et al.) images were 
obtained using a Philips CM12S Scanning Transmission Electron Microscope 
with EDAX 9800 plus energy dispersive x-ray spectrometer fitted with a Gatan 
model 791 CCD camera for direct digital image acquisition (Electron Microscopy 
Facilities, Arizona State University). The microscope was loaded with a tungsten 
film and used with an accelerating voltage of 80keV. High resolution transmission 
electron microscopy (HRTEM) images were obtained using a Philips FEI CM-200 
Transmission Electron Microscope fitted with a Gatan Orisis CCD camera for 
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image acquisition. The microscope was loaded with a field emission gun (FEG) 
and used with an accelerating voltage of 200kV.   
The average particle size was calculated by measuring the diameter of 
the particles using the Image J software (National Institutes of Health, Bethesda, 
MD). Each image was divided into four quadrants and 30 particles were 
measured at random from each quadrant, yielding a total of 120 particles per 
image. Three images were analyzed per sample.  
 
2.2.5 Relaxometry at 1.5T 
Relaxivity measurements were made with a 1.5T Minispec relaxometer 
(Bruker Optics, The Woodlands, TX.) The magnetoferritin solution was diluted 
and vortexed to make a 1% low melt agarose gel suspension. To find the 
corresponding T2 values, a Carr-Purcell-Meiboom-Gill (CPMG) sequence with 
inter pulse spacing (τ) of 20ms, gain of 70, and 200 points was used. 
Alternatively, a spin echo sequence (W. S. Seo, et al.) was performed with TE=9, 
13, 20, 31, 46, 70, 106 and 160 ms and TR=12s. In order to measure longitudinal 
relaxivity, I used an inversion recovery (IR) sequence with TI=400ms, TR=12s, 
and 16 averages. All samples were maintained at 37°C by the temperature 
controlled probe. The Bruker’s Minispec software and the exponential curve-
fitting feature were used to measure the relaxation times of each gel suspension.  
 
2.2.6 Protein Integrity Studies via Gel Electrophoresis, and Immunoprecipitation 
In order to confirm that filtered magnetoferritin was still immunologically 
equivalent to native ferritin, I performed immunopercipitation of native ferritin, 
filtered magnetoferritin, unfiltered magnetoferritin, and apoferritin. The samples 
  40 
were diluted to 30nM and labeled with anti-horse spleen ferritin antibody (Sigma 
Aldrich, St Louis). The antibody-ferritin complex was incubated with protein A 
Microbeads (Miltenyi Biotec. Gladbach, Germany) Samples were filtered using a 
magnetic column (Miltenyi Biotec, Gladbach, Germany) and rinsed with buffer. 
Samples were eluted with preheated (95°C) Novex Tris-Glycine SDS Sample 
Buffer (Invitrogen, Carlsbad CA) and incubated at room temperature for 5 
minutes. The running solution was collected while the column remained in the 
magnetic field.  
Samples were stained with Bromphenol Blue (Sigma Aldrich, St Louis) 
before loading into a 4-20% Novex Tris-glycine gel (Invitrogen, Carlsbad CA). As 
a standard I used Novex Sharp Pre-stained Protein Standards ladder (Invitrogen, 
Carlsbad CA) 10µl of stained sample was loaded into the gel wells and the gel 
was run for 100 minutes using 125 V of constant voltage, 30-40mA(start) and 8-
12mA (end). The gels were then washed and stained with Simply Blue 
(Invitrogen, Carlsbad CA) for 1 hour. 
Native Electrophoresis was also performed, and the samples were 
buffered in Novex Native Tris-Glycine Sample Buffer (Invitrogen, Carlsbad CA), 
10µl of either native ferritin, magnetoferritin, or apoferritin samples were loaded 
into wells of a 4-20% Novex Tris-glycine gel. The gel ran for 4 hours using a 
constant voltage of 125V, 6-12mA/ gel (start) and 3-6mA/gel (end). The gels 
were then washed and stained with Simply Blue (Invitrogen, Carlsbad CA) for 1 
hour.  
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2.2.7 In vivo Detection of Magnetoferritin Particles 
 All animal experiments were approved by an institutional animal care and 
use committee. In vivo injections were performed in three adult Sprague Dawley 
rats anesthetized with a Ketamine/Xylazine cocktail (90 mg/kg ketamine and 5 
mg/kg xylazine). The coordinates of injection were identified as the 
caudate/putamen and were 1.6mm anterior, 3mm lateral from the bregma and 
5mm interior from the dura. These coordinates were measured using a MRI 
compatible stereotaxic frame (David Kopf Instruments, Tujunga CA) and burr 
holes were made in the skull using a pneumatic drill. A 10µl Hamilton syringe 
was mounted onto the microinjector unit of the frame and the needle was first 
inserted 6mm interior from the dura where a pocket was formed by waiting 1 
minute at that location and retracting to 5mm interior from the dura. Once located 
in the correct coordinates 10µl of 30nM native ferritin and 30nM magnetoferritin 
were injected over the course of 5 minutes on each hemisphere of the brain 
respectively. The animal was removed from the frame after injection and placed 
inside a 7 Tesla Bruker Pharmascan scanner with a three-axis gradient slew rate 
of 150 T/m/s. The animal was supplied with constant isofluorane gas during the 
scanning experiments; Rectal temperature was monitored and regulated by a 
feedback-controlled water bath. Scans were performed using a surface  RF coil, 
gradient echo pulse sequence (TE/TR = 3.8/350ms, NEX = 4, matrix 256x192). 
 
2.3 Results and Discussion 
2.3.1 Synthesis and Particle Characterization  
Partially- filled apoferritin nanoparticles, prepared using previously 
published protocols, are shown in TEM images in Figure 10a.  Fully filled 
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magnetoferritin, prepared using the protocol outlied here, is shown in Figure 10d. 
The particles had core diameters ranging from 4nm to 6nm and HRTEM of a 
magnetoferritin particle is shown indicating crystal formation in the core of the 
protein. Bulk native ferritin contains some aggregated and partially filled cores 
(Figure 10b) and magnetically filtered native ferritin resulted in fully filled, 
aggregated sample with a low protein yield (Figure 10c). On average, 
magnetoferritin nanoparticles had larger magnetic cores (4nm-6nm) than native 
ferritin (2nm). This can be seen in Figure 10g, where 40% of the magnetoferritin 
particles ranged from 4-6nm and 50% of the native ferritin particles ranged from 
1.5-2nm.  
The yield of available protein after filtration depended on the volume of 
buffer that the particles are suspended in after filtration. When re-suspending 
200µl of the magnetically selected particles in the 200µl of 0.15M NaCl, the yield 
was 4%. As a negative control, the synthesis was performed using 48mM of 
bovine serum albumin (BSA) (Pierce Biotechnology, Rockford, IL) instead of 
apoferritin.  
  43 
 
Figure 10. TEM images of a) Magnetoferritin unfiltered following published 
protocols b) Native Ferritin c) magnetically filtered native ferritin d) Magnetically 
filtered magnetoferritin and HRTEM of a magnetoferritin particle e) Unfiltered iron 
loaded bovine serum albumin f) Magnetically filtered iron loaded bovine serum 
albumin. Scale bars are 50nm at 88kX magnification. g) Size distribution of 
magnetoferritin particles (solid line) and native ferritin particles (dashed line). 
 
 Figure 10e and f show that BSA formed amorphous and aggregated 
crystals with no distinct shape or pattern before filtration or after filtration. After 
magnetic filtration, the TEM grid did not show electron dense areas except for the 
area shown in figure 10f. Therefore, it is likely that the iron oxidized and 
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adsorbed to the BSA surface aggregating and not forming a monodisperse or 
homogeneous particle solution. 
 Here, it is demonstrated a simplified method for synthesizing an iron 
oxide based contrast agent for visualization with MRI. Iron oxide particles have 
been extensively studied, and new particles are currently synthesized to visualize 
molecular events in vivo and drug delivery agents. However, small particles (tens 
of nanometers) are difficult to develop. Ferritin can be used as a reaction 
chamber to obtain homogeneous spherical particles. Ferritin loaded with iron 
oxide allows for an easy surface conjugation to antibodies, targeting peptides, or 
fluorescent markers. In comparison to other iron oxide agents currently available, 
the proposed magnetoferritin particle is simple to create. To incorporate Fe(III) 
into the core, ferritin uses O2 as an oxidant and a catalytic site located in the 
center of the protein (Arosio, Ingrassia, & Cavadini, 2009). Two routes of iron 
loading have been identified, a catalytic pathway (due to the ferroxidase on H-
ferritin) and an auto oxidative route that becomes important once the metal core 
has started to form (Levi, et al., 1988; Yang & Chasteen, 1999). This synthesis 
likely minimizes the auto-oxidation by displacing the oxygen with N2 gas and, 
maximizes the catalytic iron deposition. This is supported by the fact that 
particles were not formed when BSA was used with same synthesis procedure.   
 
2.3.2 Protein Integrity and Relaxivity  
Native gel electrophoresis showed that native ferritin, magnetoferritin 
synthesized with the protocol outlined here, and apoferritin, all ran at the same 
molecular weight (Figure 11a).  The immunoprecipiated samples of native ferritin, 
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magnetically filtered magnetoferritin, un-filtered magnetoferritin and apoferritin all 
showed bands at 200kDa. (Figure 11b) 
 
 
Figure 11. a) Native Gel of (Lane 1)Native Ferritin (Lane 2) Magnetoferritin (Lane 
3) Apoferritin gel ran for 4.5h. b) SDS Gel of immunoprecipitated and denatured 
(Lane 1) Native Ferritin (Lane 2) Filtered Magnetoferritin (Lane 3) Unfiltered 
Magnetoferritin (Lane 4) Apoferritin. Gel was run for 100 min. 
  
Magnetically filtered magnetoferritin had a 216-fold increase in protein 
relaxivity over native ferritin, and a 25-fold increase in iron relaxivity.  In order to 
compare current relaxivity values of iron oxide particles already in use as 
contrast agents, I measured the relaxivity of magnetoferritin and native ferritin 
using a spin echo sequence. The increase is 31-fold and 275-fold of iron and 
protein relaxivity, respectively, when compared to native ferritin. Figure 12 shows 
the linear fit of the CPMG data for  magnetoferritin and native ferritin both based 
on iron and protein concentrations. Table 1 provides a summary of T1 and T2 
relaxivities using a CPMG, SE and IR pulse sequences of magnetoferritin, native 
ferritin and commercially available iron oxides. 
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Table 1.  
Magnetoferritin Relaxivity Summary  
 
 
 Transverse Relaxivity 
 CPMG Spin Echo 
 
Iron                       
(mM-1 s-1) 
Particle      
(mM-1 s-1) 
Iron                 
(mM-1 s-1) 
Particle        
(mM-1 s-
1) 
Native Ferritin 3 1868 4 2455 
Magnetoferritin 78 404045 130 675476 
10nm PDDA Iron 
Oxide 260.63 N/A* 268.2 N/A* 
 
Longitudinal Relaxivity 
Inversion Recovery 
 
Iron 
(mM-1 s-1) 
Particle 
(mM-1 s-1) 
Magnetoferritin 0.07 407 
10nm PDDA Iron 
Oxide 5.099 n/a 
10nm PDDA Iron 
Oxide R2/R1 51.11 n/a 
Magnetoferritin r2/r1 1114 993 
 
Note. Native ferritin, magnetoferritin and 10nm PDDA Iron Oxide particles 
relaxivities based on iron and particle concentrations for two types of pulse 
sequences. Carr-Purcell-Meiboom-Gill (CPMG) and Spin Echo (SE) 
sequence. The ratio is the increase in relaxivity for magnetoferritin 
compared to native (i.e. Magnetoferritin relaxivity/Native ferritin relaxivity.) 
Longitudinal relaxivity of magnetoferritin based on iron and protein 
concentrations using an inversion recovery (IR) pulse sequence. 
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Figure 12. Linear fit for magnetoferritin and native ferritin in 1% agarose gels. 
The transverse relaxation time (T2) was acquired using a CPMG pulse sequence 
in a Bruker 1.5T relaxometer with T2 exponential curve fit. 4 scans, τ = 20ms, TR 
= 15s, 200 points, at 37°C. 
Magnetic filtration is a crucial step in creating magnetoferritin 
nanoparticles with a high per-iron transverse relaxivity of 78mM-1s-1 with a CPMG 
sequence, and a 130mM-1s-1 using a Hahn spin echo pulse sequence. The per-
particle transverse relaxivity of 404,045mM-1s-1 with a CPMG sequence and 
675,476mM-1s-1 with the spin echo sequence make is possible to detect 
nanomolar concentrations of ferritin nanoparticles. Also, immunoprecipitation and 
SDS electrophoresis indicate that the protein remains intact, and has the same 
molecular weight as filtered, unfiltered, native ferritin or apoferritin. Even though it 
would be expected that denatured protein would disassemble into its subunits 
and have bands between the 15-25KDa range, it has been shown that unboiled, 
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immunoprecipitated native ferritin has prominent bands around 200KDa 
(Passaniti & Roth, 1989), which is consistent with the results. A native gel was 
also run, and native ferritin, magnetoferritin and apoferritin all ran at the same 
molecular weight.  
 
2.3.3 MRI of Magnetoferritin in vivo 
The detection of low concentrations of agents is crucial for in vivo 
imaging. To study the detection of the synthesized magnetoferritin, I injected 
30nM native ferritin or magnetoferritin into the caudate nucleus in adult rats. 
Figure 13 shows the scan of the 10µl injection of agent on each side. The image 
ipsilateral to the magnetoferritin was hypointense, indicating a strong 
susceptibility effect and T2 weighting. In contrast, native ferritin was undetectable 
at 30nM concentration and at 7 Tesla.   
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Figure 13. (a) Coronal gradient echo image of 30nM native ferritin (left) and 
Magnetoferritin (Shaw, et al.) infused into rat’s Caudate/Putamen using a syringe 
microinjector device. (TE/TR = 3.8/350ms). Inset shows the distribution of pixel 
intensities at the site of injection for Native Ferritin and for Magnetoferritin 
normalized to surrounding tissue. (n=3 rats).   
 
2.4 Conclusions 
A simple method of synthesizing iron oxide particles with commercially 
available apoferritin as the platform is introduced here. The magnetoferritin 
synthesis includes a magnetic filtration step that separates the protein cages that 
are highly filled and ferromagnetic using a permanent magnet. After exhaustive 
dialysis and magnetic separation, the particles show to be monodisperse and 
uniform in size with their core sizes ranging from 4 to 6nm. Relaxometry indicates 
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that these particles exhibit a high per-iron transverse relaxivity of 130mM-1s-1 and 
per-particle relaxivity of 404,045mM-1s-1. The fact that the protein remains 
immunologically equivalent to native ferritin and apoferritin after synthesis 
suggests that this synthesis scheme does not alter the protein antibody 
recognition sites for further detection or microscopy imaging. These results not 
only provide a facile technique for the incorporation of metallic elements inside 
the apoferritin core, but also facilitate the ability to magnetically engineer the 
crystal composition inside this versatile apoprotein platform.  
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CHAPTER 3  
FEASIBILITY STUDY OF APOFERRITIN AS A NANO-REACTOR TO TUNE r2 
AND r1 
3.1 Introduction 
 The ability to tune relaxivity in a natural nanoparticle contrast agent may 
provide unique advantages for magnetic resonance imaging. These advantages 
include the ability to tailor the desired relaxivity in a uniform and consistent 
platform such as apoferritin and increasing the detection window based on  
particle r2/r1.  Here I explore several mechanisms in which r2 and r1 can be 
manipulated within the apoferritin protein. With the knowledge obtained 
previously on the metal deposition inside ferritin, it is possible to manipulate the 
structure and compostion of the nanoparticle metal cores, and as a result tune 
the magnetic properties.  
 
3.2 Materials and Methods 
3.2.1 Materials 
 Apoferritin from horse spleen (Sigma Aldrich), Iron (Miyawaki, et al.) 
Chloride (Sigma Aldrich, 98%), 2 - N - Morpholino Ethane Sulfonic Acid (Alfa 
Aesar, 98%), Manganese (Miyawaki, et al.) Chloride (Sigma Aldrich, 1M 
solution), Sodium Tungstate Dihydrate (Sigma Aldrich), and Bovine Serum 
Albumin (Pierce Biotechnology) were used as received.  
3.2.2 Synthesis of Mn2+ Adsorbed to Magnetoferritin  
 To synthesize magnetoferritin with manganese ions adsorbed to surface 
hydrophilic channels, 2µM Apoferritin (Sigma Aldrich, St. Louis, MO) buffered in 
0.05M MES at pH 8.5, 48mM FeCl2 (Sigma Aldrich) and 4.8mM MnCl2 (Sigma 
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Aldrich) were de-aerated for 20 minutes with N2.The solution was kept in a water 
bath at 55 to 60°C. I added 125µl of and 125µl of FeCl2 in sequence to the 
apoferritin solution.  I made a total of 12 MnCl2 and 8 FeCl2 additions, ensuring 
that manganese was added first in the sequence. Samples were dialyzed against 
0.15M NaCl, and filtered using a magnetic column (Miltenyi Biotec, Galdbach, 
Germany), eluted into 0.15 NaCl buffer. As a control, 2µM bovine serum albumin 
(Thermo Scientific, Rockford, IL) was used instead of apoferritin. The sample 
was removed and dialyzed overnight against 0.15M NaCl using a 8,000 MW cut 
off dialysis tubing (BioDesignDialysis Tubing, Carmel, NY)  
 
3.2.3 Synthesis of Tungsten-Iron (WFe) Nanoparticles 
 To synthesize a tungsten and iron oxide filled apoferritin, tungstate was 
added at different rates. 2µM apoferritin (Sigma Aldrich, St. Louis, MO) was 
buffered in 0.05M Morpholino Ethanesulfoxide (MES) at pH 8.5. In separate 
containers I used 48mM FeCl2 (Sigma Aldrich), and 48mM Na2WO6 (Sigma 
Aldrich). All solutions were de-aerated for at least 15 minutes with N2, then kept 
in a water bath at 55 to 60°C under vacuum. Any apoferritin solution that 
evaporated during the de-aerating process was compensated by adding a 
previously de-aerated 0.05M MES buffer to maintain a constant volume 
throughout the reaction. I added the de-aerated 48mM FeCl2 at a rate of 
12.5µl/min, 45µl/min, and 85µl/min to the apoferritin solution using a syringe 
pump for a total of 140 minutes. Fifty minutes into FeCl2 delivery, the de-aerated 
48mM Na2WO6 was added at a rate of 12.5µl/min using a syringe pump for a 
total of 40 minutes. A total of 1.75ml of FeCl2 and 500µl of Na2WO6 were added 
to the protein solution. 200µl of 300mM sodium citrate was added to the solution 
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to chelate any remaining metal ions. The solution was then sonicated for 10 
minutes and spun for 10 minutes at 957 · g. Finally, the supernatant solution was 
collected and dialyzed overnight against 3L of de-ionized water using a 8,000 
MW cut off dialysis tubing (BioDesignDialysis Tubing, Carmel, NY). Once 
dialyzed, the protein solution was filtered using 0.8µm and 0.2µm surfactant free 
cellulose acetate syringe filters  (Corning Incorporated, Corning, NY) to rid the 
solution of coarse non-specific metal oxides. Total protein concentration was 
obtained with a Coomassie Plus Bradford Assay Kit (Thermo Scientific, Rockford, 
IL). Inductively coupled plasma – optical emission spectroscopy (ICP-OES) of 
particles suspended in 2% nitric acid was used to measure metal concentrations. 
I repeated WFe-apoferritin nanoparticle synthesis and analysis six times, with 
similar results. 
 
3.2.4 Synthesis of Mn2+ WFe Nanoparticles 
 To synthesize a tungsten and iron filled apoferritin with Mn2+ ions 
adsorbed in the pores, both previous synthesis schemes (WFe and Mn2+ - 
magnetoferritin) were combined. Firstly, a previously characterized WFe 
nanoparticle solution was obtained as described herein. The concentration of 
MnCl2 and FeCl2 solutions were tailored depending on the protein concentration. 
A ratio of 2400 Mn and 24000 Fe ions per protein was calculated. The solution 
was suspended in 0.05M MES buffer at pH 8.5. The protein solution was de-
aerated for at least 15 minutes and compensated for evaporation with previously 
de-areated and heated 0.05M MES buffer. MnCl2 and FeCl2 were pumped at a 
rate of 12.5µl/min in alternate intervals of 10 minutes each for a total of 50 
minutes.  200µl of 300mM of Sodium Citrate was added to chelate any unbound 
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metal. The solution was then sonicated for 10 minutes, spun for 10 minutes at 
957 · g. And finally, the supernatant solution was collected and dialyzed 
overnight against deionized water using a 8,000 MW cut off dialysis tubing 
(BioDesignDialysis Tubing, Carmel, NY).   
 
3.2.5 Electron Microscopy 
 Samples were adsorbed on 400 mesh Cu-C grids (Pacific GridTech, San 
Francisco, CA) and transmission electron microscopy (Artemov, et al.) images 
were obtained using a Philips CM12S Scanning Transmission Electron 
Microscope with EDAX 9800 plus an energy dispersive x-ray spectrometer fitted 
with a Gatan model 791 CCD camera for image acquisition (Electron Microscopy 
Facilities, Arizona State University). The microscope was loaded with a tungsten 
film and run at an accelerating voltage of 80keV. High Resolution Electron 
Microscopy (HREM) images were obtained using a Philips FEI CM-200 
Transmission Electron Microscope fitted with a Gatan Orisis CCD camera for 
digital image acquisition and analysis. The microscope was loaded with a field 
emission gun (FEG) and used with an accelerating voltage of 200kV.  Fast 
Fourier Transform patterns of the HRTEM images were obtained from 4 different 
particles and analyzed using ImageJ software (National Institutes of Health, 
Bethesda, MD).  
 
3.2.6 Protein and Metal Assays 
 The resulting protein concentration was obtained using the Better 
Bradford Assay (Thermo Scientific, Rockford). Briefly, known serial dilutions of 
Bovine Serum Albumin (BSA) were stained with Coomassie Plus Reagent. The 
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reagent binds with certain aminoacids, which in turn result in a spectral shift 
(from brown to blue). This shift can be measured using a spectrophotometer or a 
plate reader measuring absorbance at around 595nm. For the experiments 
presented in this work, a wavelength of 570nm was used. The Bovine Serum 
Albumin concentrations and absorbance are used as a standard curve. The 
unknown sample concentrations are then obtained by interpolating their 
absorbance to those of the BSA standard curve.  
 Metal concentrations were obtained by means of Inductively Coupled 
Plasma-Optical Emission Spectroscopy. Briefly, the unknown samples were 
suspended in a solution containing 2% Nitric Acid. The acidic sample solution 
was then sprayed into the plasma flame from the ICP-OES where the molecules 
of interest collide with the electrons from the plasma flame and produce radiation 
at specific wavelengths. This radiation is categorized by wavelength and intensity 
to determine the concentration of each element of interest. Similarly to the 
protein colorimetric assay, a standard curve is used as a reference to determine 
the overall sample metal concentrations.  
 
3.2.7 Relaxometry 
 Relaxometry was performed on the Mn2+ adsorbed magnetoferritin 
samples as follows. The samples were removed from dialysis and suspended in 
a 1% low melt agarose gel and vortexed to ensure homogeneous mixing. 
Relaxivity was measured using a MQ60 1.5T Bruker Minispec relaxometer 
(Bruker Optics, The Woodlands, TX). Bruker’s curve-fitting tool was used to find 
the corresponding T2 values using a Carr-Purcell-Meiboom-Gill pulse sequence 
(CPMG) (Inter pulse τ = 10ms, gain = 70, 200 points). T1 values were obtained 
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using the curve-fitting and the relaxation times were obtained with an Inversion 
Recovery (IR) pulse sequence (TI = 400ms, TR = 12s, 16 averages). Samples 
were maintained at 37°C during measurements.   
 Relaxometry was performed on the tungsten-iron (WFe) samples and the 
Mn2+ adsorbed to tungsten iron particles as follows. 500µl samples of different 
ferritin concentrations were prepared and mixed with 500µl of 2% agarose gel to 
yield a 1% agarose/sample mix. Each gel solution was refrigerated for at least 15 
minutes and later brought up to 370C before measurement. Relaxivity was 
measured using a MQ60 1.5T Bruker Minispec relaxometer (Bruker Optics, The 
Woodlands, TX). Bruker’s curve-fitting tool was used to find the corresponding T2 
values using a Carr-Purcell-Meiboom-Gill pulse sequence (CPMG) (Inter pulse τ 
= 4ms, gain = 62, TR = 15s, 75 points). T1 values were obtained using the curve-
fitting and the relaxation times were obtained with an Inversion Recovery pulse 
sequence (First TI = 5ms, last TI = 20,000ms, duration factor = 2.513, TR = 15s, 
8 averages, 10 points).  
 
3.2.8 Electron Paramagnetic Resonance 
 Electron paramagnetic resonance (EPR) experiments were performed at 
the EPR Facility at Arizona State University. EPR spectra were recorded at 5 K 
using a Bruker ELEXSYS 580 X-band spectrometer (Bruker, Silberstreifen, 
Germany) equipped with an Oxford Model 900 EPL liquid helium cryostat (Oxford 
Instruments, Oxfordshire, UK).  The magnetic field modulation frequency was 
100 kHz, the amplitude was 1 mT, the microwave power was 1 mW, the 
microwave frequency was approximately 9.42 GHz and the sweep time was 168 
seconds. The spectra were obtained by averaging several scans. 
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 The EPR spectra were simulated using EasySpin (v 3.1.1), a 
computational package developed by Stoll and Schweiger and based on Matlab 
(The MathWorks, Natick, MA, USA). One single Mn2+ ion (S = 5/2, I = 5/2) was 
considered for the simulations. The fitting parameters were the following: the 
isotropic g value, the line width, ∆B, the zero-field splitting parameters, D and E, 
and the isotropic hyperfine coupling, a. 
 
 3.2.9 In vivo Imaging 
 All animal experiments were approved by the animal care and use 
committee and complied with the National Institutes of Health guidelines. Adult 
male Sprague Dawley rats were anesthetized with a Ketamine/Xylazine cocktail 
(90mg/kg ketamine, 5mg/kg xylazine). The coordinates for injection were 
identified as the caudate/putamen, 1.6mm anterior, 3mm lateral (each 
hemisphere) from the bregma and 5mm interior from the dura. Once the points 
were identified, burr holes were made using a pneumatic drill. A Hamilton syringe 
was mounted onto the microinjector unit of the 900M model Stereotactic frame 
(David Kopf Instruments, Tujunga, CA). 10µl of either the experimental agent or 
native ferritin at the same concentration were injected over the course of 5min. 
Once injected, the animals were scanned in a 7T small animal, 30cm-horizontal 
bore magnet, and Biospec Advanced III Spectrometer (Bruker, Billerica, MA), 
116mm high power gradient set (600mT/m) and a whole body rat 
transmit/receive surface coil. An IRTrueFISP sequence (TE/TR= 2.2/4.4ms, flip 
angle= 60°) and a MSME sequence (TE/TR= 11/2500ms, flip angle= 180°) were 
performed to obtain the T1 and the T2 weighted images for the Mn2+ adsorbed 
mangetoferritin. While for the WFe apoferritin nanoparticles the in vivo imaging 
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parameters were the following.  The particles were injected into the striatum of a 
rat in the caudate/putamen 1.6mm anterior and 3mm lateral from the bregma. To 
breach the skull, I created two burr holes in the skull bilaterally at the stereotactic 
coordinates using a drill. A 10µL Hamilton syringe needle (Sigma Aldrich, St. 
Louis) was inserted 6mm below the dura. The needle remained in place for 1 
minute and then was retracted to 5mm below the dura. 8µL of WFe and control 
(native ferritin) were injected over the span of 5 minutes into the left and right 
hemispheres, respectively. The rat was imaged on a Bruker 7T/30 scanner 
(three-axis gradient, slew rate of 150 T/m/s) using a rat surface RF coil. 
Isofluorane gas and oxygen were delivered during the scan. To image the 
striatum, a fast low-angle shot pulse sequence (FLASH) was used (TE/TR= 
3.8ms/55.9ms, NEX 4), and a T1-map RARE pulse sequence, TE/TR = 
10.88ms/233.3ms, 500ms, 1200ms, 2500ms, 5000ms, NEX 1.   
 
3.3 Results and Discussion 
3.3.1 Synthesis and Particle Characterization 
3.3.1.1 Mn2+ Adsorbed to Hydrophilic Channels of Magnetoferritin  
 To fill the protein and adsorb Mn2+ to the hydrophilic channels, the 
reconstituted protein was synthesized by incubating 2µM apoferritin with 4.8mM 
MnCl2 and 48mM FeCl2 under N2. Briefly, four MnCl2 additions of 125µl every ten 
minutes were alternated with four additions of 48mM FeCl2 for a total reaction 
time of 200 minutes (total of 20 metal additions, 12 MnCl2 and 8 FeCl2). 
Subsequently, the product was dialyzed overnight against 0.15M NaCl and 
filtered using a magnetic column. Protein and metal concentrations were 
obtained with a Bradford assay and ICP-OES, respectively.  Incorporating iron 
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into the core through the ferroxidase of the protein and binding Mn2+ into the 
hydrophilic channels of the protein allow for the surrounding water molecules to 
interact with both the superparamagnetic crystal core and the paramagnetic ions 
as it exchanges with the bulk water (Figure 14a).   
 Transmission electron microscopy (TEM) of the resulting nanoparticles 
showed a monodisperse particle distribution and highly filled protein cores 
(Figure 14b). When bovine serum albumin was added instead of apoferritin, no 
particles formed (data not shown). Figure 14c shows the particle size distribution 
measured from images of native ferritin, magnetoferritin, and Mn2+-
Magnetoferritin. Native gel electrophoresis showed that the manganese 
magnetoferritin particles, native ferritin, and apoferritin all ran at the same 
molecular weight (Data not shown). Evidence of a crystalline oxide formation in 
the core of the protein is shown on the HREM images (Figure 14b). All particles 
in the sample had a lattice spacing of 2.5Å, consistent with the 222 and 311 inter-
planar spacing of magnetite crystals (Cranfield, et al., 2004). I conclude that the 
manganese ions did not disrupt the lattice formation of the iron oxide. 
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Figure 14. (a) Schematic Mn2+ adsorbed to a partially loaded apoferritin cavity. 
Blue circles represent Mn2+ interacting with water molecules. (b) TEM and HREM 
of Mn2+- magnetoferritin, (c) Size distribution of native ferritin (dotted line), 
magnetoferritin (solid line) and Mn2+-magnetoferritin (dashed line). Scale bars are 
50nm. 
 
3.3.1.2 Tungsten-Iron (WFe) Filled Apoferritin 
 A mixed metal oxide was formed in the apoferritin protein. Apoferritin is 
useful as a “natural” contrast agent for MRI because it is uniform in size, contains 
multiple surface functional groups, and is relatively immunologically inert 
(Beeman, Georges, & Bennett; Bulte, et al., 1995). To create the WFe composite, 
an iron oxide core was formed in apoferritin, as previously described (Jordan, 
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Caplan, & Bennett), by filling apoferritin with iron using the intrinsic ferritin 
ferroxidase.  I incorporated both tungsten and iron into the apoferritin core. After 
synthesis, dialysis, and purification, the ferritin nanoparticle core comprised an 
electron-dense metal crystal about 6nm in diameter, as demonstrated with 
transmission electron microscopy (TEM, Figure 15b). The WFe-apoferritin yield 
was 10%.  
 
Figure 15. a) Schematic illustrating the interaction between the crystal and 
the surrounding water molecules in the WFe-apoferritin particle. Yellow shell 
indicates the tungsten-iron composite surrounding a small iron oxide core. b) 
TEM and HREM of WFe-Apoferritin, electron dense cores are the composite 
formed inside the protein shell. HREM shows no lattice spacings in the crystal 
core.  
 
3.3.1.3 Mn2+ Adsorbed to Tungsten-Iron Filled Apoferritin  
 In order to optimize the r2 and r1 characteristics of the particles I combined 
the synthesis of Mn2+ adsorbed to apoferritin, and the tungsten-iron composite. 
To create this new particle, the synthesis scheme was split in two stages. The 
first stage was to load the apoferritin core with the tungsten iron composite as 
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outlined previously. Subsequently, once the tungsten-iron composite was 
characterized, the manganese ions were adsorbed onto the hydrophilic channels 
(Figure16). After synthesis, dialysis, and purification, the resulting particle 
suspension was observed under the transmission electron microscope (Artemov, 
et al.). Figure 16b shows the images of the MnWFe particles dispersed onto the 
TEM grids. The yield of reaction was 5%.  
 
 
Figure 16. a) Schematic of the particle metal atoms and their interaction with the 
water molecules. Blue circles are Mn2+ atoms adsorbed to apoferritin hydrophilic 
channels.  b) TEM and HREM of MnWFe particles. Scale bar is 50nm. 
 
3.3.2 Relaxivity and in vivo imaging 
 To determine the effectiveness of these particles, their respective 
transverse and longitudinal relaxivities were obtained for all the particles 
proposed herein.  
 Different synthesis schemes were performed to optimize the combination 
of MnCl2 and FeCl2. r1 was the most sensitive to manganese concentration; the 
optimal concentration results in a relaxivity change of approximately 80%. This is 
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likely due to the fact that Fe2+ and Mn2+ compete for the same binding sites 
located in the hydrophilic channels of the protein. Relaxometry results of particles 
synthesized with 48mM FeCl2 and 4.8mM MnCl2 showed an enhanced per-
particle and per-ion relaxivity, as shown in Table 2. Interestingly, manganese 
adsorbed particles only show an increase in r1 when the core is magnetically 
filtered and highly filled. The per-ion r1 for the Mn2+ adsorbed particles increased 
by a factor of 40 compared to MnCl2 in solution (R1= 330 mM-1s-1). Similarly, the 
per-ion r2 increased by a factor of ~10 compared to native ferritin. Using 
volumetric relaxivity, which takes into account the particle relaxivity and 
nanoparticle size, this agent is more effective than magnetoferritin as a T1 agent, 
with a volumetric relaxivity of 2.1mM-1s-1nm-3 (for Mn2+- Magnetoferritin) 
compared to 0.35mM-1s-1nm-3 (for magnetoferritin). Conversely, its volumetric T2 
relaxivity of 193.4mM-1s-1nm-3 is less than that of magnetoferritin.  
 
 Table 2 
 Mn2+ Adsorbed to Magnetoferritin Relaxivity Summary 
  
  r2 r1 
Fe 133 1.449 
Mn 31,112 338.6 
Particle 222,481 2421 
Mn2+ adsorbed 
particles 
 
Volumetric 193.40 2.10 
Fe 78 0.07 
Particle 404,045 407 
Magnetoferritin 
particles 
 Volumetric 351.23 0.35 
Mn2+ adsorbed particles, and magnetoferritin 
particles relaxivities based on iron, particle 
concentrations and volume of particle. For 
transverse (r2) and longitudinal (r1) relaxivities, a 
CPMG and an IR pulse sequence was used, 
respectively. 
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 To investigate their utility for in vivo applications, the Mn2+ magnetoferritin 
particles were injected into a rat striatum and imaged in a 7T animal scanner. 
Although the T2 relaxivity was still high in comparison to existing iron oxide 
agents, the T1 effect was nonetheless detected in vivo using an IRTrueFISP 
pulse sequence.  Figure 17 shows the stereotactic injection into the 
caudate/putamen of a male adult Sprague Dawley rat. 10µl of 76nM of agent and 
native ferritin were injected to both sides of the brain. Using the IRTruFISP pulse 
sequence the agent was detected with T1 weighting, while the native ferritin side 
did not show any hyperintensity in the area of injection. With a MSME pulse 
sequence, a T2 weighted image was created and at that concentration native 
ferritin was not detectable while the Mn2+ magnetoferritin agent showed a clear 
hypointensity on the area of injection.  
 
Figure 17. (a) 3D imaging of Sprague Dawley rats injected with 76nM native 
ferritin (left hemisphere) and manganese doped magnetoferritin (right 
hemisphere) MSME T2 map TE/TR=111/2500ms. (b) 76 nM Manganese doped 
Magnetoferritin IR TrueFISP T1 weighted image TE/TR= 2.2/4.4, flip angle= 60°, 
TI=90ms. 
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 Although this agent was detected in vivo, it is important to denote that in 
order to be able to detect this agent using T1-weighting techniques, a specific 
sequence needed to be used. The main limitation of this technique is that as it 
can be seen in Figure 17b much of the anatomical detail is lost since the 
hyperintensity was only observed at high flip angles (α=60°).  Therefore, this 
specific r2/r1 configuration poses a limitation for imaging and agents with a low 
r2/r1 are much needed.  
The tungsten-iron composites in apoferritin performed much better since they 
resulted to be agents with the lowest r2/r1 reported to date. Making them very 
attractive for in vivo imaging with T1 weighting pulse sequences. 
 
 Table 3.  
 WFe-Apoferritin Relaxometry Summary  
 
 WFe-  
apoferritin 
particle  
relaxivity 
(mM-1s-1) 
WFe - 
apoferritin 
metal 
relaxivity 
(mM-1s-1) 
WFe - 
apoferritin 
surface 
metal 
relaxivity 
(mM-1s-1) 
r1 4870.27 0.63 2.62 
r2 9076.67 1.04 4.89 
r2/r1 1.86 1.67 1.86 
 
Relaxometry of WFe-apoferritin nanoparticles 
in vitro. All relaxivity measurements were 
performed at 1.5T, 37°C with particles 
suspended in 1% agarose. T2 and T1 
relaxation times were obtained with a Carr-
Prucell-Meiboom-Gill and an Inversion 
Recovery pulse sequence, respectively.  
 
  
 The addition of sodium tungstate during reaction at different levels 
resulted in the following relaxivity profile.  
  66 
 
Figure 18. T1 relaxivity profile for increasing tungstate additions. As the rate 
increases the measured r1 decreases significantly. T2 relaxivity was not included 
in this plot as it was negligible.  
 
This technique offers a viable way to tune T1 relaxivity by tuning the tungsten 
addition rate.  
 The WFe nanoparticles had a particle r1 of 4870 ± 1199mM-1s-1 and an 
r2/r1 ratio of 1.86 at a magnetic field strength of 1.5T, as summarized in Table 4. 
To my knowledge, this is the lowest r2/r1 reported in a nanoparticle agent. 
Because the interaction between the magnetic moment of the water protons and 
the electronic moment of the nanoparticle is local, the increased r1 of the WFe 
nanoparticle is likely due to an interaction with protons at the outer surface of the 
crystal. This increased r1 can be likely due to the enhanced proton exchange at 
the surface of apoferritin observed by Vasalatyi et al. (Vasalatiy, Zhao, Zhang, 
Aime, & Sherry, 2006) To account for the expected strong surface contribution to 
r1, I computed a  “surface relaxivity” that is the atomic relaxivity of the estimated 
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number of atoms on the crystal surface (Table 3, third column). With this 
relaxivity, WFe-apoferritin should be detectable with T1-weighting in the brain, for 
example, in about 20nM-400nM concentrations, assuming a normal tissue T1 and 
T2 of 1084ms and 69ms, respectively (Stanisz, et al., 2005).  Above these 
concentrations, I expect the WFe particles to be primarily detected as T2-
shortening agents. The WFe nanoparticles are therefore practical for T1-weighted 
MRI in sub-µM concentrations, in vivo.  
 The main goal of combining the synthesis schemes (Mn2+ adsorbed 
apoferritin and the WFe composite) was to minimize the particle r2 and maximize 
the particle r1. In these particles, adding Mn2+ during synthesis led to an 
increased r2 of 29046mM-1s-1 and decrease per ion r1 to 118mM-1s-1, suggesting 
that water access to the W-Fe core is critical for the high r1 of the W-Fe 
composite nanoparticles. This combined approach particle should be detectable 
with T1-weighting in 40-125nM concentrations, narrowing the window of detection 
significantly.   
 The MnWFe particles had similar relaxivities but the per-Mn2+ r1 was 
significantly reduced when adsorbed to these WFe-filled apoferritins.  
 Table 4.  
 Mn2+ Adsorbed to WFe-Apoferritin Relaxivity Summary 
 
 Particle Metal Mn2+ 
 mM-1s-1 mM-1s-1 mM-1s-1 
r1 2306.00 0.26 118.81 
r2 29046.00 3.45 1686.63 
r2/r1 12.6 11.7 14.2 
 
Mn2+ adsorbed to WFe longitudinal and transverse 
relaxivities at were performed at 37°C, 1.5T, and in 1% 
agarose.  
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3.3.3 Solomon Bloembergen Morgan (SBM) Simulations 
 As described in the introductory section, the SBM Equations describe 
proton relaxation due to local dipolar coupling between the electronic 
paramagnetic moment and the water proton moment.   
 With this model in mind, one possible explanation for the increase in 
longitudinal relaxivity, is that by adsorbing these ions onto the channels, where 
water exchange occurs, both the inner and outer sphere relaxation contributions 
(r1IS and r1SS) are maximized. Figure 19b shows that the relaxivity of 330mM1s-1 
obtained experimentally, can be attained for a frequency of approximately 
60MHz. This result was obtained by manipulating the following parameters: 
Reducing the ionic radius (rMH), increasing the hydration number (Querol & 
Bogdanov), and the rotation correlation time (τR). In turn, I believe that the 
residence time (τM) can be increased due to apoferritin catalytic effects on water 
proton exchange. Figure 19a shows the simulated r1IS, and the residence times 
(τM) that lead to the highest relaxivities. The simulation parameters that were 
adjusted are the following: τM=50ns, τR = 50ns, rMH = 2.14 Å, qIS = 6, and qSS = 
15. All other variables were considered constant and obtained from literature 
(Caravan, et al., 2009). With these parameters, it is possible to achieve 
relaxivities that result in approximately a r1obs of 200-300mM-1s-1 for clinical field 
strengths (0.5-3T) 
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Figure 19.  a) Inner sphere relaxivity (r1IS) simulated with Solomon-Bloembergen-
Morgan model. Inner sphere relaxivity r1IS  is highest for a residence time within 
10-100ns. b) Nuclear magnetic resonance dispersion (NMRD) simulation for 
Mn2+ adsorbed Magnetoferritin showing  an observed relaxivity (r1obs) of ~300mM-
1s-1 at clinical strength frequencies (i.e. ~60mHz). 
 
3.3.4 Electron Paramagnetic Resonance 
 To confirm that the Mn2+ ions were coordinated to the protein rather than 
in solution or inserted into the iron oxide crystal core, electron paramagnetic 
resonance (EPR) was performed on a buffered MnCl2 solution, magnetoferritin 
and Mn2+-magnetoferritin. X-band EPR spectra were measured at 5 K for all 
samples. For manganese chloride in solution, a multi-line EPR spectrum is 
observed containing sixteen peaks centered at the magnetic field corresponding 
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to g = 2.0 (Figure 20, solid line top). This spectrum is very similar to those 
previously reported for Mn (Miyawaki, et al.) (Stich, et al., 2007). Figure 20 (solid 
line bottom panel) shows the EPR spectrum corresponding to Mn2+ adsorbed 
magnetoferritin. The spectrum also contains sixteen peaks centered at the field 
corresponding to g = 2.0. However, a close inspection reveals subtle differences 
in the shape and intensity of several peaks in the spectrum. Most notably, the 
resonances at the lowest g values around g = 1.89 are observably different.  
 
 
Figure 20. Original and simulated EPR spectra of MnCl2 in NaCl (top panel) and 
Mn2+ adsorbed to magnetoferritin (bottom panel). Total manganese concentration 
was 1mM.  
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 To understand the differences mentioned above, the spectra were 
simulated and fitted to the following parameters: the isotropic g value, the line 
width, DB, the zero-field splitting, D and E, and the isotropic hyperfine coupling, a 
(Weil, Bolton, & Wertz, 1994).  Figure 20 (dashed lines) also shows the simulated 
spectra. The fitting parameters corresponding to the samples are summarized in 
Table 5. Thus, the main difference between the spectra is associated with their 
line width. For MnCl2 in solution the line width is 2.2 mT, which is due to a weak 
interaction with distant protons in the solvent. Whereas for Mn2+ adsorbed 
magnetoferritin the line width is 4.0 mT (almost double). The increase in the line 
width indicates a definite coordination to the protein matrix. In which a Mn2+ ion 
interacts with other incorporated Mn2+ ions and possibly with iron ions at the core. 
Most likely, both interactions are dipole-dipole interactions. However, this 
coordination seems to be weak because the value for D is small, which is 
consistent with long electronic spin distances. In contrast, magnetoferritin only 
showed signal corresponding to Fe3+ within the crystal (g-value = 4.3). 
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 Table 5 
 EPR Parameter List 
Parameters 
MnCl2 in 
NaCl 
Mn2+ -
Magnetoferritin 
g 2.000 1.999 
ΔB 
(Nasongkla, 
et al.) 
2.2 4.0 
D (MHz) < 200 < 200 
E (MHz) < 67 < 67 
a [MHz] 268 261 
Parameters used in the simulations of EPR 
spectra of Mn2+ in solution and as bound to 
magnetoferritin. The sub-spectra corresponding 
to allowed and forbidden transitions were 
calculated separately and combined in an 
approximate 1:1 ratio to yield the final spectrum. 
 
 
3.4 Conclusions 
 I conclude that the strategic placement of manganese ions near sites of 
water exchange can significantly enhance the per-ion r1, suggesting a 
mechanism for increasing the per-ion relaxivity in porous nanoparticle agents. 
Together, the increased per-ion r1 and the EPR data indicate that the manganese 
ions are indeed coordinated to the protein and most likely clustered in the 
hydrophilic channels as identified by Wardeska et al.(Wardeska, Viglione, & 
Chasteen, 1986). Thus, by clustering the manganese ions to the channels and 
confining the water molecules within the iron crystal and the protein core, it is 
possible to enhance r1. Vasalatyi and co-workers showed that the core of the 
apoferritin protein possesses catalytic effects on the proton exchange and that it 
could be enhanced if the water exchange through the protein hydrophilic pores 
were to be hindered. Specifically for the particles in this work, it was noted that 
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the magnetic filtration step yields protein cores that are filled and likely create a 
smaller water-filled cavity. This is supported by the fact that relaxivity only 
increased in particles that were magnetically filtered.  
 The particle r1 can be increased without increasing r2 by forming a W-Fe 
composite inside apoferritin. SBM simulations support the idea that by confining 
paramagnetic moments to the surface of the particle either in the form of 
adsorbed paramagnetic atoms or in the form of uncoupled crystal surface 
moments, it is possible to maximize r1.  While allowing for water to access the 
crystal core and to interact with surface magnetic moments and also tumble at 
the right rate due to the particle size, it is possible to maximize r1 and minimize r2. 
With this low r2/r1 it is possible to detect concentrations raging in the tens of 
nanomolar in vivo.  The discovery of a synthesis scheme that results in particles 
with the lowest reported r2/r1 to date is of great interest in the field of magnetic 
resonance molecular imaging. Thus, a more in depth study of the mechanism of 
action and its applications was deemed appropriate and is presented in the 
following sections.   
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 CHAPTER 4 
CHARACTERIZATION AND ANALYSIS OF TUNGSTEN-IRON (W-FE) 
APOFERRITIN NANOPARTICLE 
4.1 Introduction 
 Researchers often improve MRI contrast agents by increasing the 
transverse (T2 or T2*) or longitudinal (T1) relaxivity. The relaxivity (r2 or r1) is a 
model of the impact of the agent on the relaxation times and consequently on 
image contrast. Since most tissues have longer intrinsic T1 compared to T2 
(Stanisz, et al., 2005) , a T1-shortening agent can be detected in ~30-fold lower 
concentrations than a T2-shortening agent of similar relaxivity. T1-shortening 
agents may also be more readily distinguished in practice because T2 or T2* 
changes can resemble intrinsic image artifacts. T1-shortening agents are often 
formed by the localized magnetic moment of unpaired electrons in a valence 
orbital of single atoms. In comparison, many T2- and T2*-shortening contrast 
agents are often formed by exchange coupling between multiple atoms in an 
oxide crystal. This coupling yields a greater net magnetic moment than the sum 
of the uncoupled moments of the component metal atoms. Thus, while T1-
shortening agents are often more desirable, T2- and T2* shortening agents can 
be more readily conferred a high relaxivity and metal payload. An example of this 
phenomenon is seen in the development of magnetic nanoparticles. Magnetic 
nanoparticles are useful as contrast agents because they are often stable in vivo, 
have a high metal payload, and can be readily functionalized. Unfortunately, 
attempts to create nanoparticle agents with high r1 usually result in a 
simultaneous enhancement in r2 and r2*(Kalman, Geninatti-Crich, & Aime; T. Kim, 
Momin, et al.; Sana, Poh, & Lim; W. S. Seo, et al., 2006; Taylor, Rieter, & Lin, 
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2008). This limits the range of concentrations over which the agent can be 
detected with T1-weighted imaging and limits the sensitivity to the imaging target.  
Several groups have developed T1-shortening agents with enhanced r1 
(Aime, Frullano, & Geninatti Crich, 2002; Kalman, et al.; T. Kim, Cho, et al.; T. 
Kim, Momin, et al.; Na, et al., 2007; Sana, et al.).  Kim et al reported a metal 
oxide based 2-10 nm particle with a relatively low r2/r1 of  ~4-25 (T. Kim, Momin, 
et al.). The smallest nanoparticles had a low r2 because of surface defects that 
created localized, rather than de-localized spins. Modulating r2/r1 with 
nanoparticle size is an important advance in nano-scale magnetism and 
magnetic resonance relaxation. Because of the wide range of applications for 
MRI contrast agents of varying sizes, there is still a need for a general, flexible 
technique to create nanoparticles with low r2/r1. 
To address this need, chemical doping is proposed to create a T1-
shortening nanoparticle with low transverse relaxivity. In crystals of 3d transition 
metals, the atoms are often coupled through electron exchange. Paramagnetic 
metals contain atoms with localized magnetic moments, either because the 
electronic wave functions of the atoms do not overlap, or because they are 
physically separated, as illustrated in Figures 21a and 21b. If a dopant is 
strategically incorporated into the metal crystal, it may be possible to prevent 
exchange coupling and localize the magnetic moments of the component atoms, 
creating a paramagnetic, T1-shortening nanoparticle contrast agent with a high 
metal payload. If established, chemical doping could facilitate metal oxide 
nanoparticles with tunable size and r2/r1. 
To investigate this concept, I formed a mixed metal oxide in the apoferritin 
protein. Apoferritin is composed of 24 subunits (of either H- or L- forms) that form 
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a spherical cage with ~ 13 nm diameter and a ~8nm core. The H-ferritin subunit 
contains a ferroxidase that converts Fe2+ to Fe3+. The ferroxidase can be used to 
create a nanoparticle contrast agent from apoferritin, suitable for in vivo targeting 
and delivery for MRI(Aime, et al., 2002; Arosio, et al., 2009; Bulte, Douglas, 
Mann, Frankel, Moskowitz, Brooks, Baumgarner, Vymazal, & Frank, 1994; 
Cormode, Jarzyna, Mulder, & Fayad; Jordan, et al.; Meldrum, Douglas, Levi, 
Arosio, & Mann, 1995; Meldrum, et al., 1992; Uchida, et al., 2008). Apoferritin is 
useful as a “natural” contrast agent for MRI because it is uniform in size, contains 
multiple surface functional groups, and is relatively immunologically inert 
(Beeman, Georges, et al.; Bulte, et al., 1995). 
 
 
Figure 21. Schematic of atomic spin coupling in a nanoparticle to form a 
superparamagnetic or paramagnetic crystal. a) De-localized electron spins in a 
super-paramagnet and localized electron spins in a paramagnet, both exposed to 
an external magnetic field. b) Metal and oxygen atoms in a spinel crystal 
arrangement with octahedral and tetrahedral sites occupied by Fe2+ or Fe3+ 
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atoms. 3d orbital and p orbital overlap, facilitating electron spin coupling. c) 
Randomly aligned spins without an external field and aligned spins with an 
external magnetic field inside the apoferritin shell. Water molecules in close 
proximity interact with the surface of the paramagnetic crystal core.  
 
4.2 Methods 
4.2.1 Synthesis of Paramagnetic WFe Nanoparticles with Different Tungsten 
Loadings 
 To synthesize a tungsten and iron oxide filled apoferritin, 2µM apoferritin 
(Sigma Aldrich, St. Louis, MO) was buffered in 0.05M Morpholino 
Ethanesulfoxide (MES) at pH 8.5. In separate containers I used 48mM FeCl2 
(Sigma Aldrich), and 48mM Na2WO6 (Sigma Aldrich). All solutions were de-
aerated for at least 15 minutes with N2, then kept in a water bath at 55 to 60°C 
under vacuum. Any apoferritin solution that evaporated during the de-aerating 
period was compensated by adding a previously de-aerated 0.05M MES buffer to 
maintain a constant volume throughout the reaction. I added the de-aerated 
48mM FeCl2 at a rate of 12.5µl/min to the apoferritin solution using a syringe 
pump for a total of 140 minutes. Fifty minutes into FeCl2 delivery, the de-aerated 
48mM Na2WO6 was added at a rate of 12.5µl/min, 45.5µl/min, and 85µl/min  
using a syringe pump for a total of 40 minutes. A total of 1.75ml of FeCl2 and 
500µl of Na2WO6 were added to the protein solution. 200µl of 300mM sodium 
citrate was added to the solution to chelate any remaining metal ions. The 
solution was then sonicated for 10 minutes and spun for 10 minutes at 957 · g. 
Finally, the supernatant solution was collected and dialyzed overnight against 3L 
of de-ionized water using a 8,000 MW cut off dialysis tubing (BioDesignDialysis 
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Tubing, Carmel, NY). Once dialyzed, the protein solution was filtered using 
0.8µm and 0.2µm surfactant free cellulose acetate syringe filters  (Corning 
Incorporated, Corning, NY) to rid the solution of coarse non-specific metal 
oxides.  
 
4.2.2 Concentration Assays and Relaxometry 
 Total protein concentration was obtained with a Coomassie Plus Bradford 
Assay Kit (Thermo Scientific, Rockford, IL) as outlined in the previous chapters. 
Inductively coupled plasma – optical emission spectroscopy (ICP-OES) of 
particles suspended in 2% nitric acid was used to measure metal concentrations 
also outlined in previous chapters.   
 
4.2.3 Size Exclusion Chromatography 
 Size exclusion chromatography (SEC) was used in order to determine the 
monodispersity of the samples and rule out non-specific oxidation outside the 
protein. Samples suspended in water were injected into a Beckman System Gold 
HPLC mounted with a Phenomenex BioSep-SEC-S4000 column and 0.05M 
NaCl at pH 7.12 mobile phase. 100µl of sample was injected at a time and 
absorbance was monitored for at least 35minutes at 280nm and 410nm for 
elution of protein and metal, respectively.   
 
4.2.4 Transmission Electron Microscopy 
 Samples were adsorbed on 400 mesh Cu-C grids (Provided by the WM 
Keck Bioimaging Laboratory) and transmission electron microscopy, TEM,  
images were obtained using a Philips CM12S Scanning Transmission Electron 
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Microscope with EDAX 9800 plus an energy dispersive x-ray spectrometer fitted 
with a Gatan model 791 CCD camera for image acquisition (Electron Microscopy 
Facilities, Arizona State University). The microscope was loaded with a tungsten 
film and run at an accelerating voltage of 80keV. High Resolution Electron 
Microscopy (HREM) images were obtained with a Philips FEI CM-200 
Transmission Electron Microscope fitted with a Gatan Orisis CCD camera for 
image capture.  
 
4.2.5 Energy Dispersive Spectroscopy 
 Energy Dispersive Spectroscopy was used as a tool to obtain elemental 
information from the particles. By focusing the electron beam to a small area full 
of particles, an energy spectrum is obtained with the distribution of elements 
coming from the grid and sample. The microscope was loaded with a field 
emission gun (FEG) and used at an accelerating voltage of 200kV. Energy 
dispersive X-Ray (EDX) spectra were obtained for native ferritin and tungsten-
iron apoferritin with a Philips FEI CM-200 mounted X-Ray for comparison. The 
microscope was then put in scanning mode to obtain Scanning Transmission 
Electron Image.  
 
4.2.6 Electron Energy Loss Spectroscopy 
 Electron Energy Loss Spectroscopy (EELS) was used to obtain elemental 
analysis and chemical composition of the crystals. EELS provides the ability to 
obtain elemental and electronic information on the oxygen K-edge and the Iron L-
edge. With this technique it is possible to differentiate between crystal structures 
of iron.  Samples were adsorbed on a Holey- copper-carbon grid (provided by the 
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LeRoy Eyring Center for Solid State Science). The samples were loaded into a 
TOPCON 002B high-resolution electron microscope running at an accelerating 
voltage of 200kV, and with a 10° double-tilt specimen holder.  
 
4.2.7 Selected Area Electron Diffraction  
 Samples were adsorbed on a holey-copper grid and loaded in a 
JEOLARM200F aberration corrected scanning transmission electron microscope. 
The scope was set to diffraction mode and the diffraction patterns were 
compared to that of a silicon standard at the same camera length to obtain the 
respective d-spacings.  
 
4.2.8 X-Ray Diffraction  
 Samples were first frozen to -80°C overnight, then lyophilized for 24 hours 
or until dry. Once dry, the powder was dispersed on a zero background holder 
with 1mm cavity and held together by applying pressure on the powder sample. 
The holder was loaded on a SIEMENS D5000 powder X-Ray Diffractometer with 
a fixed horizontal stage. X-Ray radiation was emitted by a CuKα1 source. The 
range for diffraction detection was run from 2θ values of approximately 10° to 
95°. The data was then plotted and indexed with a DIFFRAC Plus measurement 
software with EVA evaluation software.  
 
4.2.9 Superconducting Quantum Interference Device Magnetometry  
 Samples were freeze-dried using a lyophilizer after freezing at -80°C 
overnight. Each sample was weighed before measurements. The sample was 
loaded into a SQUID magnetometer sample holder. A Quantum Design MPMS-
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5S Superconducting Quantum Interference Device (SQUID) was used for all 
measurements. Hysteresis curves were obtained at 5K from +30000Oe to -
30000Oe. Zero field cooled measurements were obtained by first cooling the 
sample from room temperature to 2K at zero field. Once the temperature 
stabilized, a small field of 200Oe was turned on and magnetization 
measurements were collected upon warm up. Similarly field cooled 
measurements were performed by cooling the sample to 2K with an on-field of 
200Oe and measurements were collected during warm up. Temperature 
dependent reversal curves were performed at 5K, 10K, 50K, and 150K and the 
slope of the linear reversals were obtained for further magnetic susceptibility 
calculations, effective magnetic moment and curie constant calculations (T c). µeff 
was obtained with the formula. µeff  = 2.82√Cm µB. 
 
4.2.10 In Vitro and In Vivo MRI  
 In vitro relaxometry measurements at 7T were obtained from a T1 map of 
a 1% agarose phantom at different concentrations and with a T1-map RARE 
pulse sequence, TE/TR = 10.88ms/233.3ms,500ms, 1200ms, 2500ms, 5000ms, 
NEX 1 and heated to ~37°C using a water-bath-heated blanket.  
All in vivo animal experiments were approved by the Arizona State University 
Institutional Animal Care and Use committee. Adult  Sprague Dawley rats were 
anesthetized with a Ketamine - Xylazine cocktail (90mg/kg and 5mg/kg, 
respectively) and secured to a stereotactic frame (David Kopf Instruments, 
Tujunga, CA). The particles were injected into the striatum of a rat in the 
caudate/putamen, 1.6mm anterior and 3mm lateral from the bregma. To breach 
the skull, I created two burr holes in the skull bilaterally at the stereotactic 
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coordinates using a drill. A 10µL Hamilton syringe needle (Sigma Aldrich, St. 
Louis) was inserted 6mm below the dura. The needle remained in place for 1 
minute and then was retracted to 5mm below the dura. 8µL of WFe and control 
(native ferritin) were injected over the span of 5 minutes into the left and right 
hemispheres, respectively. The rat was imaged on a Bruker 7T/30 scanner 
(three-axis gradient, slew rate of 150 T/m/s) using a rat surface RF coil. 
Isofluorane gas and oxygen were delivered during the scan. To image the 
striatum, a fast low-angle shot pulse sequence (FLASH) was used (TE/TR= 
3.8ms/55.9ms, NEX 4), and a T1-map RARE pulse sequence, TE/TR = 
10.88ms/233.3ms, 500ms, 1200ms, 2500ms, 5000ms, NEX 1. The T1 map was 
color coded and overlaid onto a T1-weighted scan for reference. The overlay was 
set to 50% transparency using Adobe Illustrator software. 
 
4.3 Results and Discussion 
4.3.1 Synthesis and Nanoparticle Characterization  
 To create the paramagnetic WFe composite, an iron oxide core was 
formed in apoferritin, as previously described (Jordan, et al.), by filling apoferritin 
with iron using the intrinsic ferritin ferroxidase.  Then, both tungsten and iron 
were incorporated iron into the apoferritin core at the same time. After synthesis, 
dialysis, and purification, the ferritin nanoparticle core comprised an electron-
dense metal crystal about 6nm in diameter, as demonstrated with transmission 
electron microscopy (TEM, Figure 24a). The WFe-apoferritin yield was 10%, 
which is about 5 times more than that of magnetoferritin. 
The distribution of the WFe-apoferritin particle sizes, monodispersity, and 
stability were characterized with size exclusion chromatography (SEC) and 
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native gel electrophoresis as seen in Figure 22. The WFe-apoferritin particles 
were monodisperse and stable after weeks of storage Figure 22b, making them 
practical for in vivo imaging experiments.  
 
 
Figure 22. a) Native tris-glycine gel electrophoresis showing that similar 
molecular weight for the composite, native ferritin and apoferritin.  b) Photograph 
showing concentrated WFe particle solution (left) and solution after purification 
(Shaw, et al.). c) Size exclusion chromatography (SEC) of WFe nanocomposite, 
Native Ferritin, and Apoferritin, showing same elution time before, and after 
mineralization. 
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 The elution peaks were monitored by measuring absorbance of protein (280nm) 
and iron (510nm) as the particle solution traversed through the exclusion column. 
The presence of both iron and protein peaks (gray line and black dotted line 
respectively) at the same elution time indicate that the mineralization process 
and that the purification process were successful and that any non-specific 
oxidation outside the protein was discarded.  The elution time peak for the WFe-
apoferritin composite at ~20 minutes correlate with the elution time for native 
ferritin and apoferritin. These results suggest that the WFe-apoferritin 
nanoparticle is comparable to off-the-shelf native ferritin and apoferritin in 
monodispersity. The peaks obtained at ~25 minutes indicate that those are larger 
molecules taking longer to traverse through the column. This could be attributed 
to the presence of apoferritins and ferritins with a higher ratio of Heavy to light 
chain peptides. Also, possible dimers or trimers could be found when the protein 
is in its native form.  
4.3.2 Crystal Structure Characterization  
 The metal cores of the WFe nanoparticles were homogeneously filled 
(Figure 23a). There were no visible lattice fringes in high-resolution electron 
microscopy (HREM, Figure 23b). The Fourier transform of the HREM image of 
the particle, shown in the inset of Figure 23b, contained no diffraction spots, 
indicating the absence of a crystalline lattice. In contrast, the Fourier transform of 
the HREM image of native ferritin contained diffraction peaks consistent with a 
magnetite/maghemite crystal with a lattice spacing of ~ 0.25nm (see supporting 
information). The WFe-apoferritin nanoparticles were visible in scanning 
transmission electron microscopy (STEM), as shown in Figure 23c. Based on the 
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energy dispersive spectrum (EDS) across the particle, the core diameter was ~7 
nm, consistent with the inner diameter of apoferritin.  Line profiles of the EDS 
signal, shown in Figure 23c, indicated that tungsten and iron were both evenly 
distributed in the core, suggesting that both metals were incorporated evenly into 
the crystal lattice. WFe nanoparticles exhibited no X-ray diffraction patterns, 
(Figure 23d, bottom panel), confirming that cores of the WFe nanoparticles were 
amorphous. In contrast, the cores of native ferritin exhibited the characteristic 
peaks of magnetite/maghemite, (Figure 23d, top panel). WFe nanoparticles 
exhibited no distinct d-spacings in selected area electron diffraction (SAED), 
while native ferritin exhibited the characteristic d-spacings for 
magnetite/maghemite of 0.25nm, 0.205nm, 0.154nm, and 0.130nm. There were 
approximately 8788 ± 3272 metal atoms (8743±3277 iron and 77±55 tungsten) 
inside each nanoparticle, measured by inductively-coupled plasma-optical 
emission spectroscopy (ICP-OES). These data confirmed that an amorphous 
tungsten-doped nanoparticle had formed inside the apoferritin protein. 
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Figure 23. a) Transmission electron microscopy (Artemov, et al.) of WFe 
composite cores showing ~ 6-8nm cores. b) High resolution electron microscopy 
(HREM) of a WFe nanoparticle and FFT pattern inset. c) Energy Dispersive 
Spectrum (EDS) of a selected region of the WFe apoferritin. Insets: Scanning 
Transmission Electron Microscopy (STEM). Line profile indicates a ~3-4nm core 
with both W and Fe. d) X-Ray Diffraction (XRD) peaks native ferritin (top 
spectrum), and WFe nanoparticle (bottom spectrum). Selected area electron 
diffraction (SAED) of WFe (bottom panel). Native ferritin had several diffraction 
rings with d-spacings consistent with magnetite/maghemite (top panel).  
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 Electron energy loss spectroscopy was performed on native ferritin and 
the WFe-apoferritin nanoparticles to obtain the oxygen to iron ratios for each 
sample. Analyzing the signal (Si) for each edge after background subtraction can 
provide quantitative elemental information. This is due to the fact that the energy 
loss is proportional to the number of atoms giving rise to it. Colliex C et al.,  
outlined a method to determine concentration-ratios based on the signal at the 
high energy Oxygen K-edge and Iron L2,3 edge (Colliex, Manoubi, & Ortiz, 1991). 
Firstly, the background signal was substracted by a power-law model AE-r (figure 
24) Secondly, an integration area long enough to cover the L edge and the O 
edge in its entirety was selected (Δ). Finally, the integrated signal was substituted 
into the following equation.  
€ 
NFe
NO
=
SFe (α,Δ)
SO (α,Δ)
σO (α,Δ)
σFe (α,Δ)
       Eqn 21 
Using the Hartree-Slater values for the cross sections 
€ 
σO (α,Δ)
σFe (α,Δ)
, and with a  
Δ = 50eV. The ratios 
€ 
NFe
NO
 found for the particles are the following. 
 
 Table 6 
 EELS Atomic Ratios for WFe-Apoferritin Cores  
 
 
€ 
SFe (α,Δ)
SO (α,Δ)
 
€ 
σO (α,Δ)
σFe (α,Δ)
 
€ 
NFe
NO
 
Native Ferritin 0.62 0.676 0.418 
WFe-Apoferritin 0.3918 0.676  0.265 
 
EELS Iron to oxygen ratios to determine stoichiometries. Hartree-
Slater values for the O-Fe cross-sections were obtained from 
Hofer at al. (Hofer, 1991) 
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Figure 24. Complete Electron Energy Loss spectra of Native Ferritin and the 
WFe-apoferritin particles. Bottom panels display the respective O-K edge and the 
Fe L2,3 for Native Ferritin and WFe-Apoferritin nanoparticles. O K-edge and Fe-
L2,3 spectra were corrected by subtracting the delineated background lines (red 
and green respectively) 
 
 Using the atomic ratios obtained in table 6, the sample formula unit can 
be inferred. For the WFe-apoferritin it is clear that there is 3.77 times more 
oxygen atoms than iron, suggesting a formula in the following stoichiometry 
FexWyO4x. On the other hand, native ferritin calculations showed different ratios; 
there is 2.39 times more oxygen than iron in the formula unit of the crystal core. 
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The reported formula for the ferrihydrite core in native ferritin is 
[FeO(OH)]8[FeO(H2PO4)]. With a No to NFe ratio of approximately 2.33, which is in 
agreement with the EELS data. 
  
4.3.3 Magnetic Properties and Relaxivity 
 To determine whether tungsten doping made the nanoparticle 
paramagnetic, magnetometry was performed using a superconducting quantum 
interference device (SQUID). Figure 25 shows the SQUID magnetization curves 
at 5K. The WFe nanoparticles exhibited increasing magnetization with applied 
field (up to 3T), almost no saturation, and showed no hysteresis, all characteristic 
of paramagnetism. In contrast, native ferritin exhibited saturation at ±20000Oe 
and hysteresis, characteristic of superparamagnetism below the blocking 
temperature, in this case, 5K. The effective paramagnetic moment of the WFe 
particle was ~63µB based on temperature-varied measurements of magnetization 
reversals.  
 Since the calculations were performed based on molar susceptibility 
measurements, 63µB is the per-apoferritin particle moment. Thus, since the main 
paramagnetic moments present within the lattice are those of Fe3+, it is possible 
to obtain the number of paramagnetic atomic elements by dividing the total 
moment by 5µB (Fe3+ moment).  This calculation results in a total of 12.6 
paramagnetic atoms. Given that the particle T1 relaxivity was 4870mM-1s-1, it is 
possible to determine the per-paramagnetic-atom T1 relaxivity. This calculation 
then results in a per-Fe3+ relaxivity of ~386mM-1s-1  
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Figure 25. Superconducting Quantum Interference Device (SQUID) 
magnetometry for WFe-apoferritin nanoparticles. a) SQUID reversal curves for 
WFe nanoparticles and native ferritin at 5K showing paramagnetism in WFe 
nanoparticles and superparamagnetism in native ferritin. b) Temperature 
dependent magnetization reversals were performed at 5K, 10K, 50K, and 150K.   
 
 The slope of the curve as a function of temperature was measured to 
calculate the magnetic susceptibility and the Curie constant. The WFe 
nanoparticles were paramagnetic at different temperatures and exhibited curie-
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weiss paramagnetic behavior. From equation 12 the magnetic curie-weiss 
susceptibility is characterized by a shift along the temperature axis, thus the 
presence of the curie-weiss temperature “θ”. In the case of the WFe composite, 
this temperature corresponds to the point where the linear fit in figure 26 
intercepts the abscissa. This indicates that there is an exchange interaction 
between magnetic moments between atoms in the crystal in addition to an 
interaction with the external magnetic field. The positive value of θ suggests that 
the inter-atomic interaction is ferromagnetic, aligning nearest magnetic moments 
along the same directions.  
 
Figure 26. Linear fit of 1/X obtained from temperature dependent magnetization 
reversals. Only the linear portion of the curves was used for the susceptibility 
calculations.  
 
 Field cooled (FC) and zero field cooled (ZFC) magnetization 
measurements are a good way to determine the intrinsic magnetic characteristics 
of a material. Here, FC and ZFC on the tungsten-iron apoferritin and on ferritin in 
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its native form was performed. The results indicated that the paramagnetic WFe 
nanoparticles had a reduced blocking temperature (~3.5K) compared to that of 
native ferritin (~13K). (Figure 27 ZFC).  Previous ZFC and FC studies on native 
ferritin have shown a blocking temperature in agreement to what was found here, 
however, the thermal behavior when cooled at 200Oe was unusual showing a 
larger gap between the FC and the ZFC curve. This could be due to aggregation 
of the particles or a large number of magnetite ferritin particles in the sample.  
 
Figure 27. Zero field cooled (ZFC) and field cooled (FC) experiments for WFe 
nanoparticle and native ferritin. The WFe nanoparticles had an approximate Tb of 
3K while native ferritin had a Tb of approximately 13K.   
 
 These results are in agreement with the formation of a disordered and 
amorphous spin-glass like crystal. Shaw et al investigated the magnetic 
characteristics of antiferromagnetic spin glass-like iron phosphates (Shaw, et al., 
2004). The introduction of phosphates to coordinate to the iron atoms create a 
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direct linkage between phosphorous and iron bridged by oxygen. Fe-O-P. These 
amorphous materials show almost identical ZFC and FC data than the WFe 
apoferritin nanoparticle. These spin glass-like iron phosphate materials had 
susceptibility data that suggested that their paramagnetism was of curie-weiss 
type. With a Néel temperature around -80K suggesting antiferromagnetic 
coupling below the blocking temperature. Due to the antiferromagnetic spin-glass 
behavior in these iron-phosphate glasses, the FC curve shows a magnetization 
that is constant regardless of the reduction of thermal energy below the blocking 
temperature. This confirms the ferromagnetic spin coupling found below the 
blocking temperature for the WFe apoferritin composite. The FC curve illustrates 
an increase in magnetization as the thermal energy is decreased below the 
blocking temperature, which is in agreement of ferromagnetic spin coupling.  
 Taken together, the magnetization measurements confirmed that the 
WFe-apoferritin nanoparticles were paramagnetic at temperatures higher than 
3K. Also, the composite showed curie-weiss behavior similar to amorphous spin-
glasses. 
 Barbosa et al. investigated the incorporation of heteropolytungstates as 
ligands for coordination with Eu3+ lanthanides. Previous work of theirs had shown 
that polyphosphate ligands coordinated to Eu3+ resulted in stable strong 
complexing agents with powerful luminescent characteristics (Barbosa, et al., 
2010). With the premise that the ligand field can affect the spectrochemical 
emission due to energy absorption, this group studied the substitution of 
tungstate ligands instead of the polyphosphate chains. Their results showed 
nanoparticles of comparable size to the WFe-apoferritin crystals and with 
surprinsingly high 5D0 emission quantum efficiencies due to the strong ligand field 
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provided by the tungstates. This gives tremendous insight in the mechanism of 
action of the tungsten-doped iron oxide crystals. If similar to Barbosa et al, 
tungstate ligands in the WFe apoferritin crystals could be complexing the Fe3+ or 
Fe2+ atoms present within the lattice. Since tungstate imparts a strong ligand 
field, the complexed metal atoms would then be forced to have large orbital 
splittings and therefore be in a low spin state.  
 With this theory in mind, Fe2+ a d6 bare metal electronic configuration 
would then be diamagnetic in its low spin state having no unpaired electrons to 
exchange and no magnetic moment. On the other hand, Fe3+ a d5 bare metal 
electronic configuration, would then be paramagnetic with only one unpaired 
electron in its lowest energy orbital. Therefore, the magnetic moment 1µB for Fe3+ 
would most likely remain decoupled and thus the overall oxide would result in an 
amorphous paramagnetic crystal.  
 
4.3.4 In vitro Phantom and In vivo MRI 
To confirm that the WFe nanoparticles are detectable in vivo with T1-weighted 
MRI, I injected 8ul of 195nM nanoparticles into the caudate/putamen of adult 
Sprague Dawley rat brains and the same volume of native ferritin in the 
contralateral side as a control. Figure 28b shows a typical in vivo T1-weighted 
gradient-echo MRI (TE/TR=3.8ms/55.9ms) of the brain after injection, acquired at 
7T. The injection site for the WFe nanoparticles was hyperintense (left side of the 
brain). Native ferritin was not detected (right side of the brain). The T1 was 22% 
shorter at the site of WFe injection (2.02 s) than at the contralateral site of native 
ferritin (2.61 s), as shown in Figure 29c. Based on the measured r1 of WFe 
nanoparticles of 2200mM-1s-1 at 7T (Figure 28a), I estimated that ~50nM was 
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detected in vivo. Thus, WFe nanoparticles are useful as passive (un-targeted) 
agents with T1-weighted MRI at concentrations in 10s of nanomolar at 7T. 
 
 
Figure 28. WFe nanoparticles are detected in vivo with T1-weighted MRI. a) 2D 
Gradient Echo T1-weighted image of a 1% agarose phantom. Increasing 
concentrations of WFe-apoferritin result in increased positive image contrast.  b) 
3D Gradient Echo T1-weighted image of an in vivo inoculation of 8ul of 195nM 
WFe nanoparticles and native ferritin into a rat striatum. Images were acquired 
on a 7T Bruker small animal scanner. c) T1 map color overlay showing an 
average T1 for each ROI at the injection sites. The injection of WFe nanoparticle 
had an average T1 22% shorter than the contra lateral ROI. 
 
4.4 Conclusions  
Chemical doping is used to create an amorphous WFe nanoparticle with 
high T1 relaxivity.  To my knowledge this is the first report of a tungsten-doped 
iron oxide to form an MRI contrast agent. Tungstate ligands disrupted the 
exchange coupling between spins to reduce r2 and consequently reduce r2/r1. 
  96 
WFe-apoferritin nanoparticles were detected in the brain in vivo in ~10s-100s of 
nM concentrations with conventional T1-weighted MRI.  
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CHAPTER 5 
IN VIVO DETECTION OF TARGETED WFE APOFERRITIN NANOPARTICLES 
AND IN VITRO TOXICITY 
5.1 Introduction 
 The tungsten-iron apoferritin nanoparticles proved to be highly sensitive 
in vivo. Their increased r1 and reduced r2 allowed for sensitive detection of a 
bolus injection directly into the brain and imaged at 7T in a living rat. However, in 
order to prove their functionality as targeting agents the agent needs to be 
functionalized and targeted against a specific marker.  Nanoparticle T1-
shortening contrast agents are usually tested in vivo as passive targeting agents, 
namely targeting accumulation in tumors via leaky vasculature or as blood pool 
agents ((B. H. Kim, et al., 2011; Na, et al., 2007; W. S. Seo, et al., 2006), delivery 
and targeting to specific markers has been shown in very few instances 
(Geninatti Crich, et al., 2006; Kalman, Geninatti-Crich, & Aime, 2010). Aime et al 
loaded the empty cavity of apoferritin with Gd-HP-DO3A (Prohance) and also 
with approximately 1000 Mn2+ ions, functionalized the surface of the protein with 
targeting moieties to target angiogenesis of grafted tumors in mice and also to 
target hepatocarcinomas in vivo, these are some of the few examples of active 
targeted T1-shortening nanoparticles. Here, the surface of the apoferritin loaded 
with the tungsten-iron composite was cationized in order to label charged 
membranes in the kidney glomerular basement membrane. The small size of the 
particle allows the passage through fenestrated endothelia and thus the sensitive 
detection of markers and membranes in vivo without the concern of blood 
background. Finally, cellular toxicity of the composite agent is evaluated herein.  
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5.2 Methods 
5.2.1 Synthesis of Cationized Tungsten-Iron Nanoparticle “ParaCF” 
 Ferritin is readily cationized using a carbodiimide method outlined in 
Danon et al. The same method is used here to cationize the surface of the WFe 
ferritin nanoparticles, rendering what is referred to as paraCF. Once cationized, 
the resultant paraCF was dialyzed two times against phosphate buffered saline 
(PBS).  
 
5.2.2 Intravenous Injection of ParaCF in Adult Rats 
 All animal experiments were approved by the Arizona State University 
Institutional Animal Care and Use committee. Adult  Sprague Dawley rats were 
anesthetized with a Ketamine - Xylazine cocktail (90mg/kg and 5mg/kg, 
respectively). A single bolus injection of 11 mg paraCF in 1 ml PBS was 
administered intravenously in 3 male sprague-dawley rats and imaged in at small 
animal 7T Bruker scanner 1.5h after injection.  
 
5.2.3 In vivo Detection of Kidney Glomeruli, liver and spleen with MRI 
 The paraCF-injected rat was imaged 1.5 hr after injection using a T1-
weighted 2D gradient recalled echo (GRE) MRI pulse sequence (TE/TR = 10/54, 
field of view = 3x3 cm, matrix size = 256x256, slice thickness = 400 um). A naïve, 
un-injected rat was imaged using the same MRI pulse sequence and parameters. 
ParaCF labeling of the kidney glomerulus was quantified by normalizing the 
signal magnitude of the renal cortex to the muscle surrounding the spine (which 
is assumed to remain unlabeled by paraCF). The same normalization process 
was performed in the control rat. 
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 The ability to image the kidney and spleen was only attained with the 
fabrication of a custom made surface coil. To optimize the volume coverage and 
depth penetration for the in vivo rat kidney scans a surface coil was designed 
with a diameter of 4.25cm, and 2.5cm depth penetration with number of loops in 
the coil of 5 (Ncoil = 5). The surface coil was made from magnet grade wire 
(Belden, St. Louis, MO), bread-board, and non-magnetic passive trimmers 
(Johanson, Boonton, NJ and ATC, Huntington Station, NY). All passive 
components were defined to be able to tune and match directly on the resonator 
within the magnetic field and account for the impedance shift of the sample prior 
to all in vivo measurements. Subsequently, the coil was connected to a 7T 
magnet via the Avance III RF Interface Adapter T12325 (Bruker, Billerica, MA) 
and placed on the abdomen of the rats. 
 
5.2.4 Immunohistochemistry 
 Following imaging of the live rats, the animal was perfused and the 
kidneys were extracted and fixed. Following dehydration and section, the kidney 
was stained with DAPI to visualize cell nuclei. Ferritin was labeled with a rabbit 
anti-ferritin antibody and with a secondary antibody labeled with Alexa594 
against rabbit IgG. The immunostained sections were then imaged using a 
Confocal microscope.  
 
5.2.5 Cytotoxicity of WFe-Apoferritin Nanoparticles 
 A live/dead assay was performed following the instructions in the kit 
provided by the manufacturer (Biotium, Inc. Hayward, CA). Briefly, 20,000 3T3 
cells were seeded onto 24-well plates and cultured for 1 day. The cell culture 
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media supplemented per the suggested growth of 3T3 NIH cells. The cocktail 
was made up of the following. Dulbecco’s Modified Eagle Medium /+L-glutamine,  
10% Bovine Serum, and 2% Penicillin/Streptomycin. The cells were then treated 
with 0nM (DPBS), 3nM, 17nM, 33nM, or 700nM of WFe nanocomposite. The 
Calcein AM and EthD-III dyes were added to a cell-PBS mixture and let react for 
30 minutes. After such time, the fluorescence of calcein (530nM emission) and 
EthD-III (645nm emission) were obtained with an inverted fluorescence 
microscope. The live/dead percentages were obtained by means of a trypan blue 
stain. Briefly, 50µl of 0.4%Trypan blue solution was added to 50µl of the cell 
suspension prior to counting with a hemacytometer. Stained cells were counted 
as dead and accounted in the live/dead percentage calculations. 
  
5.3 Results and Discussion 
5.3.1 In vivo Detection of Kidney Glomeruli with T1-weighting  
 To confirm that WFe-apoferritin nanoparticles could also be used as 
targeted contrast agents, the surface was functionalized with amine groups to 
create a paramagnetic form of cationized ferritin (“paraCF”). Cationized ferritin 
(Figueiredo, Moreira, & Geraldes) is an example of a targeted, 
superparamagnetic contrast agent to detect and count individual glomeruli in the 
kidney with MRI (Beeman, Zhang, et al.; Bennett, Zhou, et al., 2008). CF also 
readily binds to the extracellular matrix of other organs containing fenestrated 
endothelia.  However, CF is superparamagnetic and is therefore difficult to detect 
against the blood background in vivo. Also, due to its higher T1 relaxivity, ParaCF 
may be more readily detected in non-toxic doses.  To test this, cationized WFe-
apoferritin was used using published methods(Danon, Goldstein, Marikovsky, & 
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Skutelsky, 1972) and injected it intravenously in rats. There was significant 
enhancement in in vivo MRI (Figure 29a) in the kidney and spleen compared to 
the naïve controls (Figure 29b). The image was normalized to the magnitude of 
surrounding muscle and set a threshold of 50% to map WFe-enhancement 
(Figure 29c). The labeled kidney cortex had punctate hyperintense areas, 
consistent in distribution with recent ex vivo results using CF.(Beeman, Georges, 
& Bennett, 2012) Images of control kidneys with no injections had no 
hyperintense spots (Figure 29d).  
 
Figure 29. a) In vivo intravenous injection of paraCF labeling kidney glomeruli. b) 
Control image of a rat in vivo with no injection of agent. c) Thresholded image of 
paraCF labeled and, d) no injection of agent. Highlighted in red are pixels with 
intensities 50% higher than background muscle tissue, insets show cortex of 
paraCF kidney and control kidney.  
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 It is clear that the glomeruli are labeled with paraCF showing evident 
hyperintensities in the cortex of the kidney, while control did not show significant 
enhancement over background.  
 
5.3.2 Immunohistochemistry 
 Kidneys labeled with paraCF were then isolated after perfusing the 
animal; the kidney sections were then labeled with DAPI and anti-horse spleen 
ferritin antibody with a rabbit anti-ferritin antibody followed by a goat anti-rabbit 
IgG secondary antibody labeled with Alexa594. Figure 30 below illustrates the 
clear labeling of paraCf around the glomerulus. Native ferritin, on the other hand, 
did not accumulate in the charged membrane.  
 
 
Figure 30. IHC of paraCF labeled glomerulus  (left) and native ferritin control on 
the right. Ferritin immuno-stain in red is present only on in the paraCF labeled 
kidneys. Scale bars 20µm. 
 This result confirms that the punctate hyperintensities found in the in vivo  
MRI images are indeed the result of the paramagnetic version of cationized 
ferritin, “para CF”.  
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5.3.3 Cell Viability and Toxicity 
Toxicity is important to the utility of any novel agent. To investigate the 
toxicity that the WFe-apoferritin nanoparticles may elicit to cells, adherent 3T3 
fibroblasts were incubated with 0 to 700nM of WFe apoferritin for 24 hours. And 
the viability of cells after such exposure was quantified.  
 
Figure 31. WFe nanoparticles are non-toxic in MRI-detectable 
concentrations. a) Fluorescence image of 3T3 fibroblasts incubated with WFe for 
24h. Live cells are labeled with calcein (green) and dead cells are labeled with 
EthD-III (Figueiredo, et al.) b) Viability and cytotoxicity quantitative results 
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indicating no significant cell toxicity for particle concentrations lower than 700nM. 
Error bars indicate the standard error of the mean (n=3). 
 
Cells were ~97% viable after exposure to nanoparticle concentrations lower 
than 33nM, equivalent to ~0.3mM metal (Figure 31). Cells exposed to 
concentrations above 700nM of nanoparticles were 93% viable. Therefore, the 
WFe nanoparticles are relatively non-toxic to cells in particle concentrations 
ranging from 3-700nM. These results come as no surprise, since ferritin has 
been known to be a relatively inert natural nanoparticle in the body (Cormode, et 
al., 2009). Also, cationized ferritin has been shown to be neither nephrotoxic nor 
hepatotoxic when injected intravenously in MRI-detectable concentrations 
(Beeman, et al., 2012). 
Higher particle concentrations (>700nM) may be appropriate to investigate 
the LD50 of the particles. However, such concentrations would not be 
representative of target concentrations in vivo as most targets are found in 
nanomolar to picomolar concentrations.  
 
5.4 Conclusions 
 The WFe nanoparticles were readily functionalized and detected in the 
glomerular basement membrane in vivo. The high T1 relaxivity of the agent 
allowed for the detection of individual glomerulus in vivo without the need of 
perfusing the animal. To confirm the nature of the signal, immunohistochemistry 
showed that ferritin was indeed targeted to the charged membrane of the kidney 
glomerulus. The agent was sensitive and efficient enough to be distinguishable 
above the blood background of the kidney and spleen. Also, given the 
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tremendous concern of metal toxicity, cytotoxicity studies performed in mouse 
fibroblasts after a period of incubation with the apoferritin composite particles 
showed that they are not toxic at concentrations relevant for molecular imaging in 
vivo.  
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CHAPTER 6 
SUMMARY AND FUTURE WORK 
6.1 Summary 
 Magnetic nanomaterials are important for a wide range of clinical and 
preclinical applications and rely on expertise in the physical, chemical, and 
biological aspects of both magnetization and material-biological interactions. 
Novel nanometer-scale magnetic materials, specifically functionalized and 
engineered for highly sensitive detection with MRI, open the door to tailored 
diagnostics and targeted therapy. Here, I explored the mechanisms of 
magnetization manipulation using apoferritin as a nano-reactor. Typical iron 
oxide nanoparticle contrast agents are composed of a metal oxide core stabilized 
and coated with a synthetic polymer, which in turn increases the size of the 
particle significantly. Apoferritin is uniform in size and shape and is small enough 
(8nm) to traverse through fenestrated endothelia. Apoferritin was loaded with 
magnetite crystals, adsorbed with Mn2+ ions onto the pores of its surface, and 
loaded with a tungsten-doped iron oxide crystal.   All configurations resulted in 
distinct magnetic properties; it was found that re-loading the apoferritin cavity 
with magnetite crystals gave rise to increased T2 relaxivity and low T1 relaxivity. 
Adsorbing Mn2+ ions onto the surface of magnetoferritin resulted in an increased 
per-metal and per-particle r1 that has not been reported before. However, since 
the Mn2+ could not be adsorbed without the simultaneous addition of iron, the 
particle not only had increased r1 but also a significantly high r2. This r2/r1 made it 
unfeasible for imaging with conventional T1-weighting. The addition of tungstate 
ligands during the growth of iron oxide crystal inside the apoferritin protein 
resulted in an amorphous crystal with superb r2/r1 characteristics. The chemical 
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doping of the crystal with tungsten destroyed the long-range order within the 
crystal and prevented electron exchange among neighboring metal atoms. This 
atom-isolated structure results in decoupled magnetic moments reducing the 
magnetic anisotropic energy, thus creating a paramagnetic crystal. By decoupling 
the metal magnetic moments not only was the r1 significantly increased, but also 
the r2 was reduced to levels that allowed the sensitive detection window of 20-
400nM with conventional T1-weighting pulse sequences in vivo. Finally, this 
newly synthesized and magnetically engineered particle showed excellent in vivo 
targeting characteristics when the cationized version of the particle (ParaCF) was 
injected intravenously in rats to target the negatively charged basement 
membrane of the kidney glomeruli. For the first time, individual glomeruli could be 
imaged in vivo with T1-weighting. In conclusion, the chemical doping of crystal 
oxides inside apoferritin may be a novel route towards the rational design of 
sensitive endogenous nanoparticle based T1 shortening contrast agents for 
molecular MRI.  
 
6.2 Future Work 
6.2.1 Adding Color to MRI with Doped Iron Oxide Crystals Inside Apoferritin  
 In molecular therapeutic and diagnostic research the most accurate 
methods to obtain molecular information from tissues is via ex-vivo histology. The 
level of resolution and specificity is greatly increased compared to Positron 
Emission Tomography (Medarova, et al.), Computed Tomography (CT) or MRI 
due to the use of sensitive antibody-bound fluorophores, genetically modified 
fluorescent proteins such as GFP, YFP, RFP, etc., and high resolution light 
microscopy. Although extremely specific and sensitive, their detection is only 
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achievable after biopsy or via a light endoscope. External molecular probes, such 
as quantum dots, have been developed with different wavelength emissions by 
varying their inorganic metallic core size. These sets of potentially specific and 
small probes are, however, composed of toxic metallic materials and their 
detection is limited by light penetration through tissue. Thus, there is an 
increasingly growing need to obtain similar kind of histological information in vivo, 
in three dimensions, and with high sensitivity.   
 Novel routes towards finding the “GFP” of MRI have been laid out by 
VanZijil P and coworkers with DIACEST agents as well as Pagel M and co 
workers with PARACEST, their ability to obtain multiple target differentiation 
along with internal controls puts researchers a step closer towards achieving the 
goal of “histological MR imaging” (Ali, Liu, Shah, Flask, & Pagel, 2009; 
McMahon, et al., 2008). Multiple color MRI has been accomplished only with the 
use of diamagnetic chemical exchange saturation transfer (DIACEST) 
techniques. McMahon et al developed an array of color based on small changes 
on the exchangeable protons of different diamagnetic peptides. Peptides with 
different exchange rates resulting form aminoacids such as lysine, serine, 
arginine and threonine, were separated by their individual off-resonance 
frequencies.  This very elegant and powerful technique provides with the 
capability to separate different targets within the same MR image (McMahon, et 
al., 2008).  
 With the same goal of separating different targets within the same image 
and the addition of color, I use the capability to tune relaxivity within the 
apoferritin cavity in order to obtain “colored particles”. By separating the r2/r1 of 
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different particles, it is possible to detect each particle separately by performing 
several sequential scans with different TE/TR combinations.  
 The following spin echo equation was used to simulate and predict the 
point where each particle starts to “null” itself.    
 
      Eqn.22
      
  
 
           Eqn.23  
 
 
Figure 32. Simulation of percent signal change with respect to background. Red 
color has r1= 2200mM-1s-1 and r2 = 100100mM-1s-1 . Yellow has r1= 4500mM-1s-1 
and r2= 40000mM-1s-1. Green has r1= 3950mM-1s-1 r2= 9500mM-1s-1. 100nM 
concentration of particles. 
 
 The relaxivities used in the simulations were representative of the Mn-
magnetoferritin, MnWFe, and WFe particles. However, the relaxivities in vivo are 
dependent of the static magnetic field strength.  
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Two colors were tested in vitro on an agar phantom at different concentrations. 
Figure 33 below illustrates that the experimental measurements at 7T are in 
close agreement with the simulated data. The simulation is in very good 
agreement with the experimental data. Yellow particles are to be included in the 
experiment to distinguish three colors.  
 
Figure 33. Lines represent simulated data with their respective relaxivities at 7T 
and filled markers are measured signal coming from a phantom. The multiple 
green lines represent different concentrations of contrast agent.  
 Figure 34 shows a preliminary in vitro experiment, where the green and 
red particles were imaged at varying TE/TR. Using a Matlab fitting tool it is 
possible to distinguish the cross-over points or lack there of at different 
concentrations for the particles. 
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Figure 34. Post Processing of algorithm with Matlab to distinguish red and green-
line crossover point. Red and green particles can be differentiated at different 
concentrations over background  
 Future work includes the addition of the yellow color into the scheme of 
agents and in vivo investigations. This novel acquisition technique could provide 
the ability to add color to MRI images to sensitively detect multiple targets (10s to 
100s of nanomolar) at the same time in the same scan and using the same 
endogenous particle platform.  
 
6.2.2 Cell Labeling with WFe-Apoferritin Nanoparticles 
 Nanomaterials can also be given both diagnostic and therapeutic 
capability, and imaging agents will simultaneously enable tracking of therapy.  As 
the field evolves in conjunction with an increased understanding of basic biology 
and disease, novel applications will be identified that will take advantage of these 
agents or present opportunities to develop new ones. One area of major interest 
is in tracking cells that have been labeled with nanometer- to micron-sized 
superparamagnetic particles for MRI(Bulte, 2009; Cromer Berman, Walczak, & 
Bulte; Heyn, et al., 2006; Hill, et al., 2003; Nkansah, Thakral, & Shapiro; 
Rodriguez, et al., 2006; Shapiro, Sharer, Skrtic, & Koretsky, 2006; Shapiro, 
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Skrtic, & Koretsky, 2005; Tang & Shapiro). In a notable example of the potential 
for cell tracking, “magnetovaccination” has been recently developed to facilitate 
cell-to-cell transfer of labeled magnetic antigens on a tumor and subsequent 
detection by immune cell accumulation in the lymph nodes(Long, van Laarhoven, 
Bulte, & Levitsky, 2009).  Future work would include the use of the WFe-
apoferritin nanoparticles for cell labeling and tracking. Multiple experiments to 
evaluate the labeling efficiency in cells, and possible decrease in relaxivity due to 
cell compartmentalization need to be performed. A new relaxivity metric for in-cell 
particles may need to be introduced. Finally, implementing the aforementioned 
colored particles, multiple cell populations could be tracked simultaneously in 
vivo.  
 
6.2.3 Chemical Doping with Different Ligands 
 As it was mentioned in this thesis, chemical doping with tungstate ligands 
allowed the formation of glass-like spin systems rendering amorphous crystals. 
This spin arrangement lead to an increased r1 and decreased r2 due to disruption 
of long range order and reduction of magnetic susceptibility to the paramagnetic 
regime. As shown in the introductory section, low spin Fe3+ systems result in 1µB 
uncoupled moments per atom. Thus, it is only evident that the paramagnetic 
susceptibility could be maximized if a higher paramagnetic moment could remain 
uncoupled per atom. This could be achieved either by using ligands with different 
symmetry resulting in smaller transitions (i.e. tetrahedral phosphates) or by 
doping lanthanide-oxide crystals, thus, having a large atomic moment. This could 
be accomplished by complexing a strong field ligand to Gd3+ or Eu3+ as shown by 
Barbosa and co-workers (Barbosa, et al., 2010).  
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